GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
---|
ALDH1A1 | 402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.72 | 0.684 | 33670440
|
ALDH1A1 | 402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.72 | 0.684 | 33670440
|
ALDH1A1 | 402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.72 | 0.684 | 35229723
|
ALDH1A1 | 402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.72 | 0.684 | 25881239
|
ALDH1A1 | 402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.72 | 0.684 | 25881239
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and qRT-PCR followed by Western Blotting and IF staining | NA | 0.72 | 0.684 | 32396269
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay and SFA followed by RT-PCR and Western Blotting | NA | 0.72 | 0.684 | 27836546
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and Western Blotting | NA | 0.72 | 0.684 | 32319573
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.72 | 0.684 | 30878308
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.684 | 25955300
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.684 | 28431267
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.684 | 29344850
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.684 | 31891569
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.72 | 0.684 | 28861158
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and ALDEFLUOR assay followed by Western Blotting | NA | 0.72 | 0.684 | 34163000
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by Western Blotting | NA | 0.72 | 0.684 | 29254164
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by Western Blotting and CFA | NA | 0.72 | 0.684 | 24928671
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Western Blotting | NA | 0.72 | 0.684 | 30737252
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | ALDEFLUOR assay followed by SFA and qRT-PCR | NA | 0.72 | 0.684 | 33784109
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay and qRT-PCR | NA | 0.72 | 0.684 | 32308544
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by FACs | NA | 0.72 | 0.684 | 25906011
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | CFA followed by Western Blotting | NA | 0.72 | 0.684 | 33924205
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 33980809
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 23583374
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 24247269
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 26517679
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 27836540
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 28198062
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 31207300
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.684 | 31263095
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.72 | 0.684 | 29235568
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Erlotinib | ALDEFLUOR assay followed by FACs | NA | 0.72 | 0.684 | 25125655
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by FACs | NA | 0.72 | 0.684 | 26278043
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by FACs | NA | 0.72 | 0.684 | 26278043
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Afatinib | ALDEFLUOR assay followed by FACs | NA | 0.72 | 0.684 | 30885551
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | ALDEFLUOR assay followed by FACs | NA | 0.72 | 0.684 | 30885551
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Osimertinib | ALDEFLUOR assay followed by FACs | NA | 0.72 | 0.684 | 30885551
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by FACs and SFA | NA | 0.72 | 0.684 | 28321046
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by FACs and SFA | NA | 0.72 | 0.684 | 28830450
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and ALDEFLUOR assay | NA | 0.72 | 0.684 | 29845263
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and ICC staining | NA | 0.72 | 0.684 | 31939436
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.72 | 0.684 | 34400945
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.72 | 0.684 | 34246759
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.684 | 33468994
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.684 | 34277782
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.72 | 0.684 | 26675547
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.684 | 29138851
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Tumorigenicity assay | NA | 0.72 | 0.684 | 32124474
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.72 | 0.684 | 27009878
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by SFA | NA | 0.72 | 0.684 | 33721187
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by SFA | NA | 0.72 | 0.684 | 33783940
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by SFA | NA | 0.72 | 0.684 | 33784109
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 33539684
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 34546848
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 35044041
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 35229723
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | ALDEFLUOR assay | NA | 0.72 | 0.684 | 23349823
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay | NA | 0.72 | 0.684 | 32655789
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by SFA | NA | 0.72 | 0.684 | 24607842
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ALDEFLUOR assay followed by SFA and Tumorigenicity assay | NA | 0.72 | 0.684 | 21600232
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | ALDEFLUOR assay followed by SFA and Tumorigenicity assay | NA | 0.72 | 0.684 | 26779808
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | CFA and SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 28406482
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 28400280
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 28850563
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Sorafenib | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 28850563
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 30555330
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 31466290
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 31582014
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 31928533
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 31928533
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 32033067
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 32401390
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 32612672
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ALDEFLUOR assay and Tumorigenicity assay | NA | 0.72 | 0.684 | 24013232
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by FACs | NA | 0.72 | 0.684 | 27035162
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.684 | 29416721
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.684 | 31121479
|
ALDH1A1 | 402 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by ALDEFLUOR assay | NA | 0.72 | 0.684 | 22825470
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and qRT-PCR followed by Western Blotting and IF staining | NA | 0.72 | 0.7582 | 32396269
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by qPCR and Western Blotting | NA | 0.72 | 0.7582 | 26782458
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs and IF staining followed by qRT-PCR | NA | 0.72 | 0.7582 | 31819528
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR and FACs followed by IF staining | NA | 0.72 | 0.7582 | 21947321
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | IHC staining and CFA followed by SFA and Western Blotting | NA | 0.72 | 0.7582 | 29299167
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | Western Blotting followed by ICC staining | NA | 0.72 | 0.7582 | 30341415
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | Western Blotting followed by IHC staining and SFA | NA | 0.72 | 0.7582 | 29299167
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.72 | 0.7582 | 33783940
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.7582 | 33539684
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.7582 | 25955300
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.7582 | 28431267
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.7582 | 30485693
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.7582 | 31891569
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.72 | 0.7582 | 32655789
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs and FACs followed by qRT-PCR | NA | 0.72 | 0.7582 | 28619508
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by FACs and qPCR | NA | 0.72 | 0.7582 | 26675547
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining and RT-PCR | NA | 0.72 | 0.7582 | 21520032
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and IF staining | NA | 0.72 | 0.7582 | 26239272
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and IF staining | NA | 0.72 | 0.7582 | 26261505
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and Western Blotting | NA | 0.72 | 0.7582 | 31263095
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by FACs and Western Blotting | NA | 0.72 | 0.7582 | 22370645
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Western Blotting | NA | 0.72 | 0.7582 | 28198062
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Western Blotting | NA | 0.72 | 0.7582 | 30737252
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting and FACs | NA | 0.72 | 0.7582 | 33125096
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by IF staining | NA | 0.72 | 0.7582 | 34527268
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IHC staining followed by MACs | NA | 0.72 | 0.7582 | 33887368
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining followed by SFA and FACs | NA | 0.72 | 0.7582 | 31024010
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by IF staining | NA | 0.72 | 0.7582 | 26690309
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by IF staining and CFA | NA | 0.72 | 0.7582 | 28000861
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by SFA and IF staining | NA | 0.72 | 0.7582 | 23456479
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and IF staining followed by FACs | NA | 0.72 | 0.7582 | 28534939
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR | NA | 0.72 | 0.7582 | 34400945
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.72 | 0.7582 | 29262597
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and RT-PCR followed by SFA and Tumorigenicity assay | NA | 0.72 | 0.7582 | 29225473
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs followed by RT-PCR | NA | 0.72 | 0.7582 | 24356998
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by RT-PCR | NA | 0.72 | 0.7582 | 25783528
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and RT-PCR | NA | 0.72 | 0.7582 | 25678473
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA and FACs | NA | 0.72 | 0.7582 | 25003810
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA and FACs followed by qRT-PCR and Tumorigenicity assay | NA | 0.72 | 0.7582 | 29860718
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.72 | 0.7582 | 24101104
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.72 | 0.7582 | 30816208
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and RT-PCR | NA | 0.72 | 0.7582 | 23370278
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and RT-PCR | NA | 0.72 | 0.7582 | 23715514
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR and FACs | NA | 0.72 | 0.7582 | 26299367
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | CFA followed by Western Blotting | NA | 0.72 | 0.7582 | 33924205
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.7582 | 33980809
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.72 | 0.7582 | 34803670
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.72 | 0.7582 | 33721187
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and Western Blotting | NA | 0.72 | 0.7582 | 29387193
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.7582 | 23583374
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.7582 | 24247269
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.7582 | 27836540
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.72 | 0.7582 | 31207300
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.72 | 0.7582 | 32782570
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs and FACs followed by SFA | NA | 0.72 | 0.7582 | 28854941
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs and FACs followed by SFA | NA | 0.72 | 0.7582 | 30542415
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.72 | 0.7582 | 34246759
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 33437165
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 33468994
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 34832951
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 35044041
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.72 | 0.7582 | 24646078
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.72 | 0.7582 | 29144562
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA and SP assay | NA | 0.72 | 0.7582 | 26468775
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.72 | 0.7582 | 25906011
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed +Cisplatin | RT-PCR | NA | 0.72 | 0.7582 | 26895954
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.72 | 0.7582 | 31201845
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 29044153
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 29138851
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 30981768
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.72 | 0.7582 | 30981768
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Tumorigenicity assay | NA | 0.72 | 0.7582 | 32124474
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.72 | 0.7582 | 24961511
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.72 | 0.7582 | 26546046
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.72 | 0.7582 | 27009878
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.72 | 0.7582 | 28787001
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.72 | 0.7582 | 28951614
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.72 | 0.7582 | 29414668
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by qRT-PCR | NA | 0.72 | 0.7582 | 27911857
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.72 | 0.7582 | 21347385
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.72 | 0.7582 | 22855139
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | CFA followed by FACs | NA | 0.72 | 0.7582 | 34816662
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs | NA | 0.72 | 0.7582 | 33068069
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 27920206
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 33959615
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 34827096
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 35337095
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and SFA | NA | 0.72 | 0.7582 | 34063628
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs | NA | 0.72 | 0.7582 | 33631674
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 34349823
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 34424425
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by FACs | NA | 0.72 | 0.7582 | 35267489
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | CFA and SFA followed by FACs | NA | 0.72 | 0.7582 | 28406482
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs | NA | 0.72 | 0.7582 | 23349823
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 24440048
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 27542268
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 28484448
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 28516515
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 28789457
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 31352088
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.72 | 0.7582 | 32466428
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and CFA | NA | 0.72 | 0.7582 | 32329414
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and Tumorigenicity assay | NA | 0.72 | 0.7582 | 27485114
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 24903381
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 26572130
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 26782458
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 27276704
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 28179999
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 29144562
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Dexamethasone+Pemetrexed | FACs followed by SFA | NA | 0.72 | 0.7582 | 29753869
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 31368411
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.72 | 0.7582 | 31466290
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and CFA | NA | 0.72 | 0.7582 | 29845263
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.72 | 0.7582 | 21600232
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs | NA | 0.72 | 0.7582 | 24008862
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by SFA | NA | 0.72 | 0.7582 | 22900142
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Modified PLGA magnetic SFA followed by FACs | NA | 0.72 | 0.7582 | 29843871
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 20028869
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 20028869
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 24101104
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 25965829
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 28580971
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 31121479
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 32549341
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.72 | 0.7582 | 32676335
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.72 | 0.7582 | 28202526
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and FACs | NA | 0.72 | 0.7582 | 19464919
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and SFA followed by FACs and Tumorigenicity assay | NA | 0.72 | 0.7582 | 20949018
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs and SFA | NA | 0.72 | 0.7582 | 22825470
|
PROM1 | 9454 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs and SFA | NA | 0.72 | 0.7582 | 25007054
|
EPCAM | 11529 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.56 | 0.211 | 25881239
|
EPCAM | 11529 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.56 | 0.211 | 25881239
|
EPCAM | 11529 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.56 | 0.211 | 25881239
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by IF staining and RT-PCR | NA | 0.56 | 0.211 | 21738704
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.56 | 0.211 | 33539684
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and IF staining followed by FACs | NA | 0.56 | 0.211 | 28534939
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and RT-PCR | NA | 0.56 | 0.211 | 25678473
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and RT-PCR | NA | 0.56 | 0.211 | 28854941
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR and FACs | NA | 0.56 | 0.211 | 26299367
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.56 | 0.211 | 27766570
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.56 | 0.211 | 22855139
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.56 | 0.211 | 33995625
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.56 | 0.211 | 33670440
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.56 | 0.211 | 34277782
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by Tumorigenicity assay | NA | 0.56 | 0.211 | 33707423
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture and FACs followed by SFA and Tumorigenicity assay | NA | 0.56 | 0.211 | 29017078
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.56 | 0.211 | 22498113
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.56 | 0.211 | 31692042
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Curcumin+Cisplatin | FACs followed by SFA | NA | 0.56 | 0.211 | 26531053
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.56 | 0.211 | 29868483
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and CFA | NA | 0.56 | 0.211 | 29845263
|
EPCAM | 11529 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.56 | 0.211 | 25881239
|
THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by IF staining and RT-PCR | NA | 0.56 | 0.0371 | 21738704
|
THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | IF staining followed by FACs and SFA | NA | 0.56 | 0.0371 | 31781681
|
THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by RT-PCR and SFA | NA | 0.56 | 0.0371 | 29576613
|
THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by Tumorigenicity assay | NA | 0.56 | 0.0371 | 33707423
|
THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.56 | 0.0371 | 24101104
|
THY1 | 11801 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.56 | 0.0371 | 24101104
|
POU5F1 | 9221 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.52 | 0.6448 | 35229723
|
SOX9 | 11204 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.52 | 0.0244 | 35229723
|
SOX9 | 11204 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.52 | 0.0244 | 29416721
|
SOX9 | 11204 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.52 | 0.0244 | 29416721
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | IF staining followed by Western Blotting | NA | 0.52 | 0.6448 | 34168463
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | 5-Fluorouracil | IF staining followed by Western Blotting | NA | 0.52 | 0.6448 | 34168463
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 34063628
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 33783940
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 33539684
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 34873829
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 35229723
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | CFA and SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 28406482
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.52 | 0.6448 | 28179999
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 32319573
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.52 | 0.6448 | 30878308
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 28431267
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 29344850
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 29888108
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 30485693
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 32655789
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 28861158
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.6448 | 30555330
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by Western Blotting and RT-PCR | NA | 0.52 | 0.6448 | 24333218
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining and RT-PCR | NA | 0.52 | 0.6448 | 21520032
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and IF staining | NA | 0.52 | 0.6448 | 24101104
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and IF staining | NA | 0.52 | 0.6448 | 26239272
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by IF staining | NA | 0.52 | 0.6448 | 21124918
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.52 | 0.6448 | 29262597
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs followed by RT-PCR | NA | 0.52 | 0.6448 | 24356998
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and RT-PCR | NA | 0.52 | 0.6448 | 28854941
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.52 | 0.6448 | 28534939
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA followed by FACs and qRT-PCR | NA | 0.52 | 0.6448 | 29860718
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.52 | 0.6448 | 30816208
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.52 | 0.6448 | 33707423
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and Western Blotting | NA | 0.52 | 0.6448 | 34163000
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 33980809
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 34949193
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.52 | 0.6448 | 34803670
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 33721187
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA and Western Blotting | NA | 0.52 | 0.6448 | 26779808
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and Western Blotting | NA | 0.52 | 0.6448 | 29387193
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by CFA and Western Blotting | NA | 0.52 | 0.6448 | 32637578
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 21425153
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 21802163
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 22370645
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 23583374
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 24013232
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 24386189
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 26517679
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 29299167
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 29299167
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 29416721
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 31207300
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 31263095
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 31928533
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 33125096
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SP assay followed by Western Blotting | NA | 0.52 | 0.6448 | 23022172
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting | NA | 0.52 | 0.6448 | 23349823
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.52 | 0.6448 | 29254164
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | Western Blotting | NA | 0.52 | 0.6448 | 30341415
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting | NA | 0.52 | 0.6448 | 31282010
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting followed by Migration assay | NA | 0.52 | 0.6448 | 20074550
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | Western Blotting followed by SFA | NA | 0.52 | 0.6448 | 29299167
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.52 | 0.6448 | 24668028
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.52 | 0.6448 | 26261505
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | CFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 33924205
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR | NA | 0.52 | 0.6448 | 33068069
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.52 | 0.6448 | 33995625
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.52 | 0.6448 | 34400945
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and SFA | NA | 0.52 | 0.6448 | 33784109
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA | NA | 0.52 | 0.6448 | 33670440
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 33437165
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 33468994
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 34209829
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 34277782
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 34832951
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 35044041
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 34681614
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture and SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 29017078
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | qPCR | NA | 0.52 | 0.6448 | 26181204
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | qPCR | NA | 0.52 | 0.6448 | 26181204
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.52 | 0.6448 | 24646078
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.52 | 0.6448 | 29144562
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA and SP assay | NA | 0.52 | 0.6448 | 26468775
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.6448 | 22300949
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed +Cisplatin | RT-PCR | NA | 0.52 | 0.6448 | 26895954
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.6448 | 26940223
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.6448 | 26940223
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.6448 | 31201845
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by CFA | NA | 0.52 | 0.6448 | 29995950
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.52 | 0.6448 | 25003810
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.52 | 0.6448 | 29225473
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.52 | 0.6448 | 31368411
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.6448 | 28850563
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Regorafenib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.6448 | 28850563
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Sorafenib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.6448 | 28850563
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.52 | 0.6448 | 26675547
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 22900142
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 24101104
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 27766570
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 28035349
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 29044153
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 29138851
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 29448000
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 31024010
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 32401390
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 32612672
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 32655321
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 26546046
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 27009878
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 28787001
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.6448 | 31582014
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.52 | 0.6448 | 28456659
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 31871777
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by qRT-PCR | NA | 0.52 | 0.6448 | 23009336
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.52 | 0.6448 | 22615765
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.52 | 0.6448 | 22825470
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.52 | 0.6448 | 21947321
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Dexamethasone+Pemetrexed | FACs followed by SFA | NA | 0.52 | 0.6448 | 29753869
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and SFA followed by FACs and Tumorigenicity assay | NA | 0.52 | 0.6448 | 20949018
|
POU5F1 | 9221 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs and SFA | NA | 0.52 | 0.6448 | 26081992
|
PRDX2 | 9353 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | Western Blotting followed by ICC staining | NA | 0.52 | 0.0074 | 30341415
|
PRDX6 | 16753 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | IF staining followed by Western Blotting | NA | 0.52 | 0.0042 | 31819528
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining and Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 35278461
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 34063628
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 34065942
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 33783940
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 34873829
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 35229723
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | CFA and SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 28406482
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.52 | 0.5695 | 28179999
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.52 | 0.5695 | 30878308
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and qRT-PCR followed by Western Blotting | NA | 0.52 | 0.5695 | 32396269
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 25955300
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 29888108
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 30485693
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 32655789
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 30555330
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.52 | 0.5695 | 22615765
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining and RT-PCR | NA | 0.52 | 0.5695 | 21520032
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and IF staining | NA | 0.52 | 0.5695 | 26239272
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs followed by RT-PCR | NA | 0.52 | 0.5695 | 24356998
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.52 | 0.5695 | 30816208
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.52 | 0.5695 | 33707423
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and Western Blotting | NA | 0.52 | 0.5695 | 34163000
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 33980809
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 34949193
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 33721187
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA and Western Blotting | NA | 0.52 | 0.5695 | 26779808
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by CFA and Western Blotting | NA | 0.52 | 0.5695 | 32637578
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 21425153
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 21802163
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 22370645
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 24013232
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 29299167
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 29416721
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31207300
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31263095
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31658996
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 31928533
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 33125096
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting | NA | 0.52 | 0.5695 | 23349823
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.52 | 0.5695 | 29254164
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | Western Blotting | NA | 0.52 | 0.5695 | 30341415
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | Western Blotting followed by SFA | NA | 0.52 | 0.5695 | 29299167
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.52 | 0.5695 | 26261505
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | CFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 33924205
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.52 | 0.5695 | 33995625
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.52 | 0.5695 | 34400945
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and SFA | NA | 0.52 | 0.5695 | 33784109
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and SFA | NA | 0.52 | 0.5695 | 34246759
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA | NA | 0.52 | 0.5695 | 33670440
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 33437165
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 34209829
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 34277782
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 34832951
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.5695 | 34681614
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture and SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 29017078
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | qPCR | NA | 0.52 | 0.5695 | 26181204
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.52 | 0.5695 | 24646078
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.52 | 0.5695 | 29144562
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA and SP assay | NA | 0.52 | 0.5695 | 26468775
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.5695 | 25906011
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.5695 | 26940223
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.52 | 0.5695 | 31201845
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by CFA | NA | 0.52 | 0.5695 | 29995950
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.52 | 0.5695 | 25003810
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.52 | 0.5695 | 31368411
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.5695 | 28850563
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Regorafenib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.5695 | 28850563
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Sorafenib | SFA and CFA followed by RT-PCR | NA | 0.52 | 0.5695 | 28850563
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.52 | 0.5695 | 26675547
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.52 | 0.5695 | 31796785
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 22900142
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 24101104
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 24101104
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | 5-Fluorouracil | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 25683371
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 25683371
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 27766570
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 28035349
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 29044153
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 29448000
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 31024010
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 32033067
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 32401390
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 32655321
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.5695 | 23370278
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.5695 | 26546046
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.52 | 0.5695 | 27009878
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.52 | 0.5695 | 29414668
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.52 | 0.5695 | 28456659
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and SFA followed by qRT-PCR | NA | 0.52 | 0.5695 | 31871777
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by qRT-PCR | NA | 0.52 | 0.5695 | 23009336
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Trichostatin | SP assay followed by qRT-PCR | NA | 0.52 | 0.5695 | 27418136
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by SFA and RT-PCR | NA | 0.52 | 0.5695 | 28440478
|
SOX2 | 11195 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.52 | 0.5695 | 21947321
|
SOX9 | 11204 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining and Western Blotting followed by SFA | NA | 0.52 | 0.0244 | 35278461
|
VTCN1 | 28873 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining and Western Blotting followed by SFA | NA | 0.52 | 0.0021 | 35278461
|
ABCG2 | 74 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.48 | 0.1739 | 25881239
|
ABCG2 | 74 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.48 | 0.1739 | 25881239
|
ABCG2 | 74 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Gene ChIP analysis | Up | 0.48 | 0.1739 | 18423378
|
ABCG2 | 74 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.48 | 0.1739 | 18034892
|
ALDH1A3 | 409 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.48 | 0.0201 | 25881239
|
ALDH1A3 | 409 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.48 | 0.0201 | 25881239
|
ALDH1A3 | 409 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.48 | 0.0201 | 25881239
|
ALDH1A3 | 409 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.48 | 0.0201 | 25881239
|
CD44 | 1681 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.48 | 1 | 35229723
|
MCL1 | 6943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.48 | 0.0032 | 25881239
|
MIR19A | 31574 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.48 | 0.0064 | 22301433
|
SIRPG | 15757 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.48 | 0.0021 | 29416721
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1739 | 28861158
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting and qRT-PCR | NA | 0.48 | 0.1739 | 25200103
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting and SP assay followed by qRT-PCR | NA | 0.48 | 0.1739 | 23009336
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | MACs followed by Western Blotting | NA | 0.48 | 0.1739 | 31819528
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | 5-fluorouracil | FACs followed by qRT-PCR | NA | 0.48 | 0.1739 | 22416214
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Methotrexate | FACs followed by qRT-PCR | NA | 0.48 | 0.1739 | 22416214
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs followed by RT-PCR | NA | 0.48 | 0.1739 | 24356998
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SP assay followed by FACs and RT-PCR | NA | 0.48 | 0.1739 | 24009622
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs and RT-PCR | NA | 0.48 | 0.1739 | 25988710
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.48 | 0.1739 | 33707423
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 33980809
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and Western Blotting | NA | 0.48 | 0.1739 | 31871777
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining followed by SP assay | NA | 0.48 | 0.1739 | 25810011
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by IHC staining and Tumorigenicity assay | NA | 0.48 | 0.1739 | 29552128
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR | NA | 0.48 | 0.1739 | 33068069
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA and SP assay | NA | 0.48 | 0.1739 | 26468775
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.1739 | 31368411
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1739 | 22900142
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 0.1739 | 24961511
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.48 | 0.1739 | 24961511
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1739 | 28951614
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1739 | 29414668
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by qRT-PCR | NA | 0.48 | 0.1739 | 27911857
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.1739 | 21347385
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.1739 | 22615765
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.1739 | 22855139
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs and SFA | NA | 0.48 | 0.1739 | 26081992
|
ABCG2 | 74 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SP assay followed by FACs and Tumorigenicity assay | NA | 0.48 | 0.1739 | 22844424
|
ALDH1A3 | 409 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0201 | 27836546
|
ALDH1A3 | 409 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and Western Blotting | NA | 0.48 | 0.0201 | 34163000
|
ALDH1A3 | 409 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.48 | 0.0201 | 29235568
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1135 | 30555330
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by Western Blotting and RT-PCR | NA | 0.48 | 0.1135 | 24333218
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by CFA and Western Blotting | NA | 0.48 | 0.1135 | 32637578
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.48 | 0.1135 | 22370645
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | SFA followed by Western Blotting | NA | 0.48 | 0.1135 | 32726929
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1135 | 32782570
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | Western Blotting followed by SFA | NA | 0.48 | 0.1135 | 29299167
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1135 | 34681614
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1135 | 34681614
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1135 | 29138851
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1135 | 21520032
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1135 | 29414668
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 0.1135 | 21124918
|
BMI1 | 1066 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Dexamethasone+Pemetrexed | FACs followed by SFA | NA | 0.48 | 0.1135 | 29753869
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and Western Blotting | NA | 0.48 | 1 | 34065942
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 1 | 25955300
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 1 | 28431267
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 1 | 32655789
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining and RT-PCR | NA | 0.48 | 1 | 21520032
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and FACs followed by Western Blotting | NA | 0.48 | 1 | 34163000
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Western Blotting | NA | 0.48 | 1 | 34949193
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and Western Blotting followed by SFA | NA | 0.48 | 1 | 28259998
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by IF staining | NA | 0.48 | 1 | 34527268
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | IF staining followed by FACs and SFA | NA | 0.48 | 1 | 31781681
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining followed by SFA and FACs | NA | 0.48 | 1 | 31024010
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by SFA and ICC staining | NA | 0.48 | 1 | 31939436
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR | NA | 0.48 | 1 | 34400945
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and RT-PCR | NA | 0.48 | 1 | 28854941
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA and FACs | NA | 0.48 | 1 | 25003810
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.48 | 1 | 30816208
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | CFA followed by Western Blotting | NA | 0.48 | 1 | 33924205
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 33980809
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.48 | 1 | 35278461
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by CFA and Western Blotting | NA | 0.48 | 1 | 32637578
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 23773734
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 24247269
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 27836540
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 28198062
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 28741092
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | SFA followed by Western Blotting | NA | 0.48 | 1 | 32726929
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 32782570
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 33125096
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.48 | 1 | 29254164
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.48 | 1 | 29552200
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ICC staining | NA | 0.48 | 1 | 31582014
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.48 | 1 | 23947765
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.48 | 1 | 26261505
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.48 | 1 | 34246759
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 33437165
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 34832951
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed +Cisplatin | RT-PCR | NA | 0.48 | 1 | 26895954
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.48 | 1 | 31201845
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and qPCR followed by Tumorigenicity assay | NA | 0.48 | 1 | 31796785
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 1 | 24961511
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 1 | 29044153
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Tumorigenicity assay | NA | 0.48 | 1 | 32124474
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.48 | 1 | 24961511
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 1 | 28951614
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | CFA followed by FACs | NA | 0.48 | 1 | 34816662
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs | NA | 0.48 | 1 | 33068069
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.48 | 1 | 33784109
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs followed by SFA | NA | 0.48 | 1 | 33784109
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.48 | 1 | 34277782
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by FACs | NA | 0.48 | 1 | 35267489
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture and FACs followed by SFA and Tumorigenicity assay | NA | 0.48 | 1 | 29017078
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 22498113
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs | NA | 0.48 | 1 | 23349823
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 26278043
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 26278043
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 28516515
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 28789457
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 31352088
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.48 | 1 | 32466428
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and Tumorigenicity assay | NA | 0.48 | 1 | 27485114
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.48 | 1 | 29144562
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Dexamethasone+Pemetrexed | FACs followed by SFA | NA | 0.48 | 1 | 29753869
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.48 | 1 | 29868483
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and CFA | NA | 0.48 | 1 | 29845263
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.48 | 1 | 25965829
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by FACs | NA | 0.48 | 1 | 27035162
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.48 | 1 | 30555330
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by FACs | NA | 0.48 | 1 | 32655321
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.48 | 1 | 25881239
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and SFA followed by FACs and Tumorigenicity assay | NA | 0.48 | 1 | 20949018
|
CD44 | 1681 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs | NA | 0.48 | 1 | 22825470
|
EZH2 | 3527 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting and qRT-PCR followed by CFA and Migration Invasion assay | NA | 0.48 | 0.0074 | 29156731
|
GLI1 | 4317 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by qPCR and Western Blotting | NA | 0.48 | 0.0308 | 34424425
|
HOXD8 | 5139 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.0011 | 27748920
|
IKZF3 | 13178 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.0032 | 30816208
|
IL6 | 6018 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | ELISA and qPCR followed by SFA and Migration Invasion assay | NA | 0.48 | 0.0191 | 26675547
|
IL6 | 6018 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR and Tumorigenicity assay | NA | 0.48 | 0.0191 | 27009878
|
JARID2 | 6196 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and Western Blotting and SFA | NA | 0.48 | 0.0032 | 34246759
|
KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0891 | 34873829
|
KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.0891 | 28179999
|
KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0891 | 30555330
|
KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.48 | 0.0891 | 33995625
|
KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.0891 | 33670440
|
KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.48 | 0.0891 | 25906011
|
KLF4 | 6348 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.48 | 0.0891 | 28456659
|
LIN28A | 15986 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.0138 | 28179999
|
LIN28A | 15986 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.0138 | 29262597
|
MCL1 | 6943 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 23418490
|
MIR19A | 31574 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0064 | 28431267
|
MIR19B1 | 31575 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0042 | 28431267
|
MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.1304 | 30485693
|
MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1304 | 30555330
|
MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1304 | 22615765
|
MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 33980809
|
MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 22370645
|
MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1304 | 34681614
|
MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.1304 | 29225473
|
MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1304 | 32033067
|
MYC | 7553 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.48 | 0.1304 | 28456659
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 34063628
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 34065942
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 35229723
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | CFA and SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 28406482
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.5461 | 28179999
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and qRT-PCR followed by Western Blotting | NA | 0.48 | 0.5461 | 32396269
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 28431267
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 29344850
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 29888108
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 30485693
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 32655789
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 30555330
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by Western Blotting and RT-PCR | NA | 0.48 | 0.5461 | 24333218
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining and RT-PCR | NA | 0.48 | 0.5461 | 21520032
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.5461 | 29262597
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | FACs followed by RT-PCR | NA | 0.48 | 0.5461 | 24356998
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA and RT-PCR | NA | 0.48 | 0.5461 | 28854941
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.48 | 0.5461 | 28534939
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA followed by FACs and qRT-PCR | NA | 0.48 | 0.5461 | 29860718
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and qRT-PCR | NA | 0.48 | 0.5461 | 30816208
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR and FACs | NA | 0.48 | 0.5461 | 26299367
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.48 | 0.5461 | 33707423
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 33980809
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 34949193
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 35267489
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 33721187
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA and Western Blotting | NA | 0.48 | 0.5461 | 26779808
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and Western Blotting | NA | 0.48 | 0.5461 | 29387193
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by CFA and Western Blotting | NA | 0.48 | 0.5461 | 32637578
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 21425153
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 21802163
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 22370645
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 26517679
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 27836540
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 28198062
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 29416721
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 31928533
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 32782570
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 33125096
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting | NA | 0.48 | 0.5461 | 23349823
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | Western Blotting | NA | 0.48 | 0.5461 | 30341415
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.48 | 0.5461 | 26261505
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IHC staining | NA | 0.48 | 0.5461 | 24668028
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR | NA | 0.48 | 0.5461 | 33068069
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.48 | 0.5461 | 33995625
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.48 | 0.5461 | 34400945
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and SFA | NA | 0.48 | 0.5461 | 33784109
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.5461 | 33670440
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 33437165
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 33468994
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34209829
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34277782
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34832951
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 35044041
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture and SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 29017078
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | qPCR | NA | 0.48 | 0.5461 | 26181204
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.48 | 0.5461 | 24646078
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA and SP assay | NA | 0.48 | 0.5461 | 26468775
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed +Cisplatin | RT-PCR | NA | 0.48 | 0.5461 | 26895954
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR | NA | 0.48 | 0.5461 | 31201845
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.5461 | 25003810
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.5461 | 29225473
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.5461 | 31368411
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.48 | 0.5461 | 26675547
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.48 | 0.5461 | 31796785
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 22900142
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | 5-Fluorouracil | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 25683371
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 25683371
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 27766570
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 28035349
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 29138851
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 29448000
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 31024010
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 32033067
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 32401390
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 32612672
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 32655321
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 23370278
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 26546046
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 27009878
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 28787001
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 31582014
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 31871777
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by qRT-PCR | NA | 0.48 | 0.5461 | 23009336
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.5461 | 22615765
|
NANOG | 20857 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.48 | 0.5461 | 22825470
|
NOTCH1 | 7881 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0477 | 30555330
|
NOTCH1 | 7881 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0477 | 31939436
|
NOTCH1 | 7881 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0477 | 22615765
|
NOTCH1 | 7881 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | SFA followed by Western Blotting | NA | 0.48 | 0.0477 | 32726929
|
PAX6 | 8620 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting and RT-PCR followed by SFA and Migration Invasion assay | NA | 0.48 | 0.0021 | 31024010
|
PHC3 | 15682 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by qPCR and Western Blotting | NA | 0.48 | 0.0021 | 34424425
|
SHH | 10848 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by qPCR and Western Blotting | NA | 0.48 | 0.0201 | 34424425
|
SHH | 10848 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0201 | 30555330
|
SHH | 10848 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.0201 | 29262597
|
SIRPG | 15757 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0021 | 35229723
|
SMO | 11119 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by qPCR and Western Blotting | NA | 0.48 | 0.0212 | 34424425
|
SMO | 11119 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.0212 | 29225473
|
SOX5 | 11201 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Western Blotting followed by SFA and Migration Invasion assay | NA | 0.48 | 0.0011 | 29888108
|
TGIF2 | 15764 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay and Western Blotting followed by qRT-PCR and SFA | NA | 0.48 | 0.0021 | 31871777
|
WNT1 | 12774 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0074 | 22615765
|
WNT1 | 12774 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting | NA | 0.48 | 0.0074 | 31819528
|
WNT2 | 12780 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 22615765
|
YAP1 | 16262 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0117 | 30128013
|
YAP1 | 16262 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by qRT-PCR | NA | 0.48 | 0.0117 | 27911857
|
FOXF1 | 3809 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and IF staining followed by SFA and Tumorigenicity assay | NA | 0.44 | 0.0032 | 32319573
|
CACNA2D1 | 1399 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.4 | 0.0064 | 25881239
|
CACNA2D1 | 1399 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.4 | 0.0064 | 25881239
|
CXCR4 | 2561 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.4 | 0.0498 | 34059086
|
CXCR4 | 2561 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.4 | 0.0498 | 34059086
|
CXCR4 | 2561 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.4 | 0.0498 | 34059086
|
MYH9 | 7579 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.4 | 0.0064 | 34059086
|
MYH9 | 7579 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.4 | 0.0064 | 25881239
|
CACNA2D1 | 1399 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by Tumorigenicity assay and SFA and Western Blotting | NA | 0.4 | 0.0064 | 33707423
|
CACNA2D1 | 1399 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by qPCR and SFA | NA | 0.4 | 0.0064 | 30464601
|
CXCR4 | 2561 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by FACs and Western Blotting | NA | 0.4 | 0.0498 | 22370645
|
CXCR4 | 2561 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA and Western Blotting | NA | 0.4 | 0.0498 | 26779808
|
CXCR4 | 2561 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs | NA | 0.4 | 0.0498 | 33068069
|
CXCR4 | 2561 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and CFA | NA | 0.4 | 0.0498 | 32329414
|
MYH9 | 7579 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Western Blotting | NA | 0.4 | 0.0064 | 34635641
|
RASSF1 | 9882 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Western Blotting | NA | 0.4 | 0.0021 | 25007054
|
NCAM1 | 7656 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.36 | 0.0074 | 29416721
|
NCAM1 | 7656 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.36 | 0.0074 | 29416721
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | IF staining followed by SFA and FACs | NA | 0.36 | 0.0583 | 31024010
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.36 | 0.0583 | 23947765
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.36 | 0.0583 | 31582014
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs | NA | 0.36 | 0.0583 | 33068069
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.36 | 0.0583 | 33995625
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.36 | 0.0583 | 33670440
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.36 | 0.0583 | 33707423
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs | NA | 0.36 | 0.0583 | 33631674
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Curcumin+Cisplatin | FACs followed by SFA | NA | 0.36 | 0.0583 | 26531053
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.36 | 0.0583 | 29868483
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by FACs | NA | 0.36 | 0.0583 | 32655321
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.36 | 0.0583 | 25881239
|
ALCAM | 400 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.36 | 0.0583 | 29187584
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by SFA and ICC staining | NA | 0.36 | 0.456 | 31939436
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | RT-PCR followed by SFA and FACs | NA | 0.36 | 0.456 | 25003810
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by ICC staining | NA | 0.36 | 0.456 | 31582014
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by qRT-PCR | NA | 0.36 | 0.456 | 24961511
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by RT-PCR | NA | 0.36 | 0.456 | 24961511
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture and FACs followed by SFA and Tumorigenicity assay | NA | 0.36 | 0.456 | 29017078
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.36 | 0.456 | 26278043
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.36 | 0.456 | 26278043
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.36 | 0.456 | 28789457
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | MACs followed by Tumorigenicity assay | NA | 0.36 | 0.456 | 31796785
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 30555330
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs | NA | 0.36 | 0.456 | 22825470
|
NCAM1 | 7656 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by IF staining | NA | 0.36 | 0.0074 | 34527268
|
NCAM1 | 7656 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.36 | 0.0074 | 32466428
|
ALDH1A2 | 15472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.32 | 0.0117 | 25881239
|
EXO1 | 3511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Transcriptomics followed by Western Blotting | Up | 0.32 | 0.0042 | 24440048
|
EXO1 | 3511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.32 | 0.0042 | 25881239
|
MSH2 | 7325 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Transcriptomics followed by Western Blotting | Up | 0.32 | 0.0021 | 24440048
|
RAD51 | 9817 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Transcriptomics followed by Western Blotting | Up | 0.32 | 0.0032 | 24440048
|
XRCC6 | 4055 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Transcriptomics followed by Western Blotting | Up | 0.32 | 0.0053 | 24440048
|
ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR | NA | 0.32 | 0.0604 | 34400945
|
ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.32 | 0.0604 | 33980809
|
ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.32 | 0.0604 | 22900142
|
ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.32 | 0.0604 | 22615765
|
ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.32 | 0.0604 | 22855139
|
ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SP assay and Tumorigenicity assay | NA | 0.32 | 0.0604 | 26940223
|
ABCB1 | 40 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by FACs and SFA | NA | 0.32 | 0.0604 | 26081992
|
ALDH1A2 | 15472 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.32 | 0.0117 | 29262597
|
ALDH1A2 | 15472 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Pemetrexed | ALDEFLUOR assay | NA | 0.32 | 0.0117 | 26181204
|
MIR5100 | 43540 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by FACs and SFA | NA | 0.32 | 0.0011 | 29144562
|
NES | 7756 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Paclitaxel | SFA followed by FACs and qRT-PCR | NA | 0.32 | 0.0573 | 29860718
|
NRP1 | 8004 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs and SFA followed by qRT-PCR | NA | 0.32 | 0.0053 | 29138851
|
ABCC1 | 51 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.28 | 0.0212 | 25881239
|
CCND1 | 1582 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0201 | 34059086
|
CLOCK | 2082 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0021 | 25881239
|
CLOCK | 2082 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0021 | 25881239
|
COL17A1 | 2194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.28 | 0.0064 | 29416721
|
COL17A1 | 2194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0064 | 25881239
|
COL17A1 | 2194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0064 | 25881239
|
CTNNB1 | 2514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0647 | 34059086
|
CTNNB1 | 2514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0647 | 25881239
|
GSTP1 | 4638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0053 | 34059086
|
GSTP1 | 4638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0053 | 34059086
|
NOTCH2 | 7882 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0117 | 34059086
|
TGFB1 | 11766 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.28 | 0.0138 | 25432175
|
TGFB1 | 11766 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0138 | 34059086
|
TM4SF4 | 11856 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.28 | 0.0032 | 25881239
|
TM4SF4 | 11856 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.28 | 0.0032 | 25881239
|
TSPYL5 | 29367 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.28 | 0.0032 | 25881239
|
USP4 | 12627 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0021 | 25881239
|
USP4 | 12627 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.28 | 0.0021 | 25881239
|
ABCC1 | 51 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0212 | 33980809
|
ABCC1 | 51 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.0212 | 25683371
|
BACH1 | 935 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0011 | 34949193
|
CAMK2G | 1463 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.28 | 0.0021 | 25965829
|
CCND1 | 1582 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0201 | 33980809
|
CDK1 | 1722 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0011 | 33721187
|
CLOCK | 2082 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 33125096
|
COL17A1 | 2194 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0064 | 31928533
|
CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 33980809
|
CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 24013232
|
CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 27836540
|
CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting | NA | 0.28 | 0.0647 | 31819528
|
CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | Western Blotting followed by Migration assay | NA | 0.28 | 0.0647 | 20074550
|
CTNNB1 | 2514 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | qRT-PCR and SFA | NA | 0.28 | 0.0647 | 34246759
|
GSTP1 | 4638 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0053 | 34840986
|
ITGB1 | 6153 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and Western Blotting followed by Tumorigenicity assay | NA | 0.28 | 0.018 | 30485693
|
KCNK3 | 6278 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA and Migration assay | NA | 0.28 | 0.0021 | 29387193
|
LGR5 | 4504 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by CFA and Western Blotting | NA | 0.28 | 0.0753 | 32637578
|
LGR5 | 4504 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and SFA | NA | 0.28 | 0.0753 | 34246759
|
LGR5 | 4504 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.28 | 0.0753 | 31796785
|
MSI1 | 7330 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by Western Blotting | NA | 0.28 | 0.0201 | 22370645
|
MSI1 | 7330 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0201 | 23715514
|
NOTCH2 | 7882 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0117 | 24013232
|
NOTCH2 | 7882 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting | NA | 0.28 | 0.0117 | 29254164
|
RXRA | 10477 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0021 | 30058740
|
SNAI1 | 11128 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and Western Blotting | NA | 0.28 | 0.0212 | 34163000
|
SNAI1 | 11128 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by Western Blotting | NA | 0.28 | 0.0212 | 35267489
|
SNAI1 | 11128 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR | NA | 0.28 | 0.0212 | 34400945
|
SNAI1 | 11128 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.0212 | 32033067
|
TGFB1 | 11766 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA and Migration Invasion assay | NA | 0.28 | 0.0138 | 32606331
|
TGFB1 | 11766 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by Migration and Invasion assay | NA | 0.28 | 0.0138 | 28789457
|
TM4SF4 | 11856 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA and Migration Invasion assay | NA | 0.28 | 0.0032 | 29254164
|
TSPYL5 | 29367 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and Western Blotting | NA | 0.28 | 0.0032 | 34163000
|
UBE3C | 16803 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting and SFA followed by Migration and Invasion assay | NA | 0.28 | 0.0021 | 30503554
|
USP4 | 12627 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0021 | 32549341
|
VIM | 12692 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Irradiation | SFA and Western Blotting | NA | 0.28 | 0.017 | 34163000
|
VIM | 12692 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Cisplatin | SFA followed by Western Blotting | NA | 0.28 | 0.017 | 35267489
|
YBX1 | 8014 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | Western Blotting followed by Invasion assay and SFA | NA | 0.28 | 0.0021 | 28400280
|
AKR1C1 | 384 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.24 | 0.0085 | 33670440
|
AKR1C1 | 384 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0085 | 25881239
|
AKR1C2 | 385 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.24 | 0.0053 | 33670440
|
AKR1C2 | 385 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0053 | 25881239
|
BMP6 | 1073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25432175
|
BMP6 | 1073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0021 | 25881239
|
CCL2 | 10618 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0074 | 25432175
|
CCL2 | 10618 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0074 | 34059086
|
CCL2 | 10618 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.24 | 0.0074 | 25881239
|
CCL5 | 10632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0064 | 25432175
|
CCL5 | 10632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.24 | 0.0064 | 35229723
|
CRLF1 | 2364 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 25432175
|
CSF2 | 2434 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25432175
|
CSF3 | 2438 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 25432175
|
CYR61 | 2654 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 25432175
|
CYR61 | 2654 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0053 | 34059086
|
CYR61 | 2654 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0053 | 25881239
|
CYR61 | 2654 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0053 | 25881239
|
EDIL3 | 3173 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25432175
|
GAL | 4114 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 25432175
|
IL11 | 5966 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 25432175
|
IL8 | 6025 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0159 | 25432175
|
IL8 | 6025 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0159 | 25881239
|
INHA | 6065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 25432175
|
INHBA | 6066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 25432175
|
INHBA | 6066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 25432175
|
INHBA | 6066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0042 | 25881239
|
INHBA | 6066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0042 | 25881239
|
INHBB | 6067 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0064 | 25432175
|
INHBC | 6068 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 25432175
|
INHBE | 24029 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25432175
|
MIR210 | 31587 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0064 | 22301433
|
MIR26B | 31612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and RT-PCR | Down | 0.24 | 0.0032 | 22301433
|
MIR26B | 31612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.24 | 0.0032 | 33959615
|
MIR26B | 31612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.24 | 0.0032 | 33959615
|
MIR31 | 31630 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and RT-PCR | Down | 0.24 | 0.0064 | 22301433
|
MIR497 | 32088 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.24 | 0.0053 | 31692042
|
MIRLET7C | 31480 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and RT-PCR | Down | 0.24 | 0.0042 | 22301433
|
MIRLET7E | 31482 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and RT-PCR | Down | 0.24 | 0.0032 | 22301433
|
NODAL | 7865 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 25432175
|
PDGFA | 8799 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25432175
|
PDGFA | 8799 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0021 | 25881239
|
PDGFB | 8800 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 25432175
|
PTHLH | 9607 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 25432175
|
PTHLH | 9607 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0042 | 25881239
|
PTHLH | 9607 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.24 | 0.0042 | 25881239
|
TGFB2 | 11768 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0074 | 25432175
|
TGFB3 | 11769 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 25432175
|
AKR1C1 | 384 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0085 | 18034892
|
AKR1C2 | 385 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 18034892
|
MIR130B | 31515 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 28534939
|
MIR181B1 | 31550 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 28534939
|
MIR25 | 31609 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 28534939
|
MIR302A | 31623 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 28534939
|
MIR302C | 31764 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 28534939
|
MIR497 | 32088 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0053 | 28534939
|
MIR671 | 33134 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 28534939
|
MIRLET7E | 31482 | HTM/LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 28534939
|
ATXN1 | 10548 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.24 | 0.0064 | 21520032
|
ATXN1 | 10548 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by IF staining | NA | 0.24 | 0.0064 | 26261505
|
MIR31 | 31630 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Up | 0.24 | 0.0064 | 34277782
|
MIRLET7C | 31480 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.24 | 0.0042 | 34277782
|
CEACAM1 | 1814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0064 | 35229723
|
CEACAM1 | 1814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0064 | 29416721
|
CEACAM1 | 1814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0064 | 29416721
|
CEACAM1 | 1814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0064 | 29416721
|
CEACAM1 | 1814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.2 | 0.0064 | 29416721
|
MIR30A | 31624 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.2 | 0.0085 | 31692042
|
MIR30A | 31624 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.2 | 0.0085 | 31692042
|
MIR582 | 32838 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.2 | 0.0064 | 22301433
|
MIRLET7F1 | 31483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.2 | 0.0053 | 31692042
|
MIRLET7G | 31485 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.2 | 0.0032 | 22301433
|
ZEB1 | 11642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.2 | 0.0074 | 25881239
|
ZEB1 | 11642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.2 | 0.0074 | 25881239
|
ABCA2 | 32 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by invasion assay and RT-PCR | NA | 0.2 | 0.0021 | 17510412
|
CD34 | 1662 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0053 | 30981768
|
CD34 | 1662 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0053 | 21520032
|
CD34 | 1662 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | Gefitinib | SFA followed by FACs | NA | 0.2 | 0.0053 | 22370645
|
CEACAM1 | 1814 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by RT-PCR | NA | 0.2 | 0.0064 | 22855139
|
DNMT1 | 2976 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 29044153
|
KIT | 6342 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.018 | 21520032
|
KIT | 6342 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.2 | 0.018 | 20028869
|
KIT | 6342 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by FACs | NA | 0.2 | 0.018 | 20028869
|
MACsC1-AS1 | 41257 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 32401390
|
MIR145 | 31532 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0032 | 34277782
|
MIR181C | 31552 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0032 | 34277782
|
MIR196B | 31790 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Up | 0.2 | 0.0021 | 34277782
|
MIR212 | 31589 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Up | 0.2 | 0.0021 | 34277782
|
MIR30A | 31624 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0085 | 34277782
|
MIR410 | 32065 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR followed by SFA and Tumorigenicity assay | NA | 0.2 | 0.0011 | 28076327
|
MIR490 | 32075 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0011 | 34277782
|
MIR582 | 32838 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Up | 0.2 | 0.0064 | 34277782
|
MIR582 | 32838 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | qRT-PCR and Tumorigenicity assay followed by SFA | NA | 0.2 | 0.0064 | 26468775
|
MIR873 | 33663 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Up | 0.2 | 0.0021 | 34277782
|
MIR99A | 31650 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0021 | 34277782
|
MIRLET7F1 | 31483 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0053 | 34277782
|
MIRLET7G | 31485 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | BME based 3D culture followed by qRT-PCR | Down | 0.2 | 0.0032 | 34277782
|
SLC7A5 | 11063 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0042 | 34681614
|
TMPRSS4 | 11878 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by RT-PCR and Migration Invasion assay | NA | 0.2 | 0.0042 | 26546046
|
TWIST2 | 20670 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.2 | 0.0011 | 33468994
|
ZEB1 | 11642 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qPCR | NA | 0.2 | 0.0074 | 33468994
|
ZNF322 | 23640 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 30258097
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by SFA | NA | 0.12 | 0.456 | 34277782
|
CD24 | 1645 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs followed by Tumorigenicity assay | NA | 0.12 | 0.456 | 33707423
|
DRD2 | 3023 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs | NA | 0.12 | 0.0011 | 27920206
|
TRPM7 | 17994 | LTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by SFA and FACs | NA | 0.12 | 0.0021 | 30477473
|
ACTB | 132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 33670440
|
ACTN4 | 166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0074 | 33670440
|
AHSG | 349 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0011 | 33670440
|
AKR1B10 | 382 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
AKR1B10 | 382 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0042 | 25881239
|
AKR1B10 | 382 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0042 | 25881239
|
AKR1C3 | 386 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
AKR1C3 | 386 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0042 | 25881239
|
AKR1C3 | 386 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0042 | 25881239
|
AKR1C4 | 387 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 33670440
|
ALDOA | 414 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
ANXA1 | 533 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0053 | 33670440
|
ANXA1 | 533 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0053 | 33670440
|
CLU | 2095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0064 | 33670440
|
CLU | 2095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0064 | 33670440
|
CLU | 2095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0064 | 25881239
|
CLU | 2095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0064 | 25881239
|
CST3 | 2475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0011 | 33670440
|
ENO1 | 3350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0095 | 33670440
|
FN1 | 3778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0053 | 33670440
|
FN1 | 3778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.08 | 0.0053 | 29416721
|
FN1 | 3778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.08 | 0.0053 | 29416721
|
FN1 | 3778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.08 | 0.0053 | 29416721
|
FN1 | 3778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.08 | 0.0053 | 29416721
|
GAPDH | 4141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0053 | 33670440
|
GAS2L1 | 16955 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 33670440
|
IGFBP4 | 5473 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
IGFBP4 | 5473 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
IGFBP4 | 5473 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0042 | 25881239
|
IGFBP4 | 5473 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0042 | 25881239
|
KRT8 | 6446 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0074 | 33670440
|
KRT8 | 6446 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0074 | 33670440
|
KRT8 | 6446 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0074 | 25881239
|
KRT8 | 6446 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.08 | 0.0074 | 25881239
|
PFN1 | 8881 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
PRSS1 | 9475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0032 | 33670440
|
PRSS1 | 9475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.08 | 0.0032 | 25881239
|
PRSS1 | 9475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.08 | 0.0032 | 25881239
|
PRSS3 | 9486 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 33670440
|
PRSS3 | 9486 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.08 | 0.0021 | 25881239
|
PRSS3 | 9486 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.08 | 0.0021 | 25881239
|
PRSS3 | 9486 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.08 | 0.0021 | 25881239
|
S100A6 | 10496 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0053 | 33670440
|
TMSB10 | 11879 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0011 | 33670440
|
TMSB4X | 11881 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 33670440
|
TNP1 | 11951 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0011 | 33670440
|
YWHAB | 12849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0032 | 33670440
|
YWHAB | 12849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.08 | 0.0032 | 34059086
|
YWHAQ | 12854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0032 | 33670440
|
YWHAZ | 12855 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 33670440
|
A1CF | 24086 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
AAGAB | 25662 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
AAMP | 18 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
AARS1 | 20 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
AASS | 17366 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
AASS | 17366 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
AATK | 21 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ABCA12 | 14637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 29316740
|
ABCA12 | 14637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
ABCA12 | 14637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
ABCC10 | 52 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ABCC2 | 53 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0106 | 25881239
|
ABCC2 | 53 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0106 | 25881239
|
ABCC2 | 53 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Gene ChIP analysis | Up | 0.04 | 0.0106 | 18423378
|
ABCC3 | 54 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
ABCC3 | 54 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
ABCC4 | 55 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
ABCC4 | 55 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
ABCG1 | 73 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 35229723
|
ABCG1 | 73 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
ABHD4 | 20154 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ABHD5 | 21396 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ABRACL | 21230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ABTB2 | 23842 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ACADSB | 91 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ACADSB | 91 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ACAT2 | 94 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ACAT2 | 94 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ACBD5 | 23338 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ACCS | 23989 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ACO2 | 118 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
ACOT2 | 18431 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 29316740
|
ACOT2 | 18431 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ACP1 | 122 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ACP6 | 29609 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
ACSL4 | 3571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ACSL4 | 3571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ACSM3 | 10522 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ACSM3 | 10522 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ACSS1 | 16091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ACSS1 | 16091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ACSS1 | 16091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ACTN1 | 163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
ACTN1 | 163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ADAM12 | 190 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
ADAM23 | 202 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ADAM23 | 202 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ADAM28 | 206 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ADAM28 | 206 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ADAMTS1 | 217 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ADAMTS1 | 217 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ADAMTS13 | 1366 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ADAMTS6 | 222 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ADAMTS6 | 222 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ADCY1 | 232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
ADCY3 | 234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ADCY7 | 238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ADGRA3 | 13839 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ADGRE2 | 3337 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29416721
|
ADGRG2 | 4516 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ADGRG2 | 4516 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ADGRG6 | 13841 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ADGRL4 | 20822 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ADGRV1 | 17416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
ADH6 | 255 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ADK | 257 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ADK | 257 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ADM | 259 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
ADORA2B | 264 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
ADORA2B | 264 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
ADRA1B | 278 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
AFDN | 7137 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
AFDN | 7137 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
AFMID | 20910 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
AGMAT | 18407 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
AGO2 | 3263 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
AGO2 | 3263 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
AGR2 | 328 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
AGT | 333 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
AHI1-DT | 32526 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
AHNAK | 347 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
AHSA1 | 1189 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
AHSA1 | 1189 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
AIFM1 | 8768 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
AIG1 | 21607 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
AK4 | 363 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
AK4 | 363 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
AK7 | 20091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
AKAP12 | 370 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
AKAP13 | 371 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
AKR1B1 | 381 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
AKR1B1 | 381 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
AKR1E2 | 23437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
AKR7A2 | 389 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
AKT3 | 393 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
AKT3 | 393 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ALDH3A1 | 405 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 35229723
|
ALDH3A1 | 405 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 34059086
|
ALDOC | 418 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ALDOC | 418 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ALG1 | 18294 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ALG8 | 23161 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ALKBH2 | 32487 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ALKBH2 | 32487 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ALPK2 | 20565 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ALPK2 | 20565 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ALX1 | 1494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ALX1 | 1494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
AMDHD1 | 28577 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
AMIGO1 | 20824 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
AMIGO2 | 24073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
AMN1 | 27281 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
AMOTL1 | 17811 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
AMOTL1 | 17811 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
AMZ2P1 | 26491 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ANG | 483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ANG | 483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ANGPT1 | 484 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
ANK3 | 494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ANKRD1 | 15819 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ANKRD1 | 15819 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ANKRD20A11P | 42024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ANKRD20A12P | 43603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ANKRD20A2P | 31979 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ANKRD20A8P | 23666 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ANKRD20A8P | 23666 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ANKRD22 | 28321 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ANKRD50 | 29223 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ANKRD50 | 29223 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ANKRD52 | 26614 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ANKS4B | 26795 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
ANKZF1 | 25527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ANKZF1 | 25527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ANKZF1 | 25527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ANO1 | 21625 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ANO1 | 21625 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ANO4 | 23837 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ANO4 | 23837 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ANO5 | 27337 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ANO5 | 27337 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ANO5 | 27337 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ANP32C | 16675 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ANPEP | 500 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0117 | 25881239
|
ANTXR1 | 21014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
ANTXR1 | 21014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
ANTXR2 | 21732 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
ANTXR2 | 21732 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
ANTXR2 | 21732 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
ANXA13 | 536 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ANXA13 | 536 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ANXA3 | 541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0085 | 25881239
|
ANXA3 | 541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0085 | 25881239
|
ANXA4 | 542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ANXA4 | 542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ANXA8 | 546 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ANXA8L1 | 23334 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ANXA8L1 | 23334 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ANXA8L1 | 23334 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
AOX1 | 553 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
AOX1 | 553 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
AP3S2 | 571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
AP3S2 | 571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
AP5B1 | 25104 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
AP5S1 | 15875 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
APBB2 | 582 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
APBB2 | 582 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
APLP2 | 598 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
APOBEC3A | 17343 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
APOBEC3B | 17352 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
APOBEC3F | 17356 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
APOD | 612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 35229723
|
APOD | 612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
APOH | 616 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
APOH | 616 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
AR | 644 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
AR | 644 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ARAP2 | 16924 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
AREG | 651 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
AREG | 651 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
AREG | 651 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
ARG2 | 664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 35229723
|
ARG2 | 664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
ARHGAP11A | 15783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ARHGAP12 | 16348 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ARHGAP23 | 29293 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ARHGAP26 | 17073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ARHGAP29 | 30207 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ARHGAP42 | 26545 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ARHGAP42 | 26545 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ARHGDIB | 679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
ARHGDIB | 679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
ARHGEF17 | 21726 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ARHGEF17 | 21726 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
ARHGEF18 | 17090 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ARHGEF35 | 33846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ARHGEF35 | 33846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ARHGEF39 | 25909 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ARHGEF5 | 13209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ARHGEF5 | 13209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ARHGEF5 | 13209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ARHGEF5 | 13209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ARID3B | 14350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ARID4A | 9885 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ARID5B | 17362 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ARL4C | 698 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ARNTL2 | 18984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ARNTL2 | 18984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ARRB1 | 711 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ARRB2 | 712 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ARRB2 | 712 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ARSD | 717 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ARSJ | 26286 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ARSJ | 26286 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ARSL | 719 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ARSL | 719 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
AS3MT | 17452 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ASAP2 | 2721 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ASAP2 | 2721 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ASB1 | 16011 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ASB4 | 16009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ASGR1 | 742 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ASGR1 | 742 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ASIC4 | 21263 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ASRGL1 | 16448 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
ATAD2B | 29230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ATF7IP2 | 20397 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ATP10D | 13549 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ATP10D | 13549 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ATP11B | 13553 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ATP2B1 | 814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ATP2B1 | 814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ATP2B4 | 817 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ATP2B4 | 817 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ATP5G1 | 841 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ATP6V0D1 | 13724 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ATP7A | 869 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ATP7A | 869 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ATP8B1 | 3706 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ATP9A | 13540 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ATRX | 886 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ATRX | 886 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ATRX | 886 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ATXN8 | 32925 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
AVEN | 13509 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
AVP | 894 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
AVPI1 | 30898 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
AXIN1 | 903 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
B3GALNT1 | 918 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
B3GALNT1 | 918 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
B3GNT3 | 13528 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
B3GNT5 | 15684 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
B3GNT5 | 15684 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
B4GALNT1 | 4117 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
B4GALT4 | 927 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
B4GALT4 | 927 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
B4GALT6 | 929 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
BAAT | 932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
BABAM2 | 1106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
BACE2 | 934 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
BAG2 | 938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
BAG6 | 13919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
BAHCC1 | 29279 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
BAMBI | 30251 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
BAMBI | 30251 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
BANF1 | 17397 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
BARX2 | 956 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
BASP1 | 957 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
BAX | 959 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
BBS4 | 969 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
BCAR3 | 973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
BCAR3 | 973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
BCAS1 | 974 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
BCAS3 | 14347 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
BCAT1 | 976 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
BCL10 | 989 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
BCL2A1 | 991 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
BCL2L15 | 33624 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
BCL2L15 | 33624 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
BCO1 | 13815 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
BCO2 | 18503 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
BCOR | 20893 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
BCOR | 20893 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
BCR | 1014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
BCR | 1014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
BDNF | 1033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
BDNF | 1033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
BEND4 | 23815 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
BEND7 | 23514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
BFAR | 17613 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
BICC1 | 19351 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
BICC1 | 19351 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
BIRC3 | 591 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
BIRC3 | 591 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
BIRC3 | 591 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
BIRC5 | 593 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
BLM | 1058 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
BLM | 1058 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
BLMH | 1059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
BLVRB | 1063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
BMPR1B | 1077 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
BMPR1B | 1077 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
BNC1 | 1081 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
BNC1 | 1081 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
BNC2 | 30988 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
BORCS7-ASMT | 49183 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
BRCA1 | 1100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
BRCA1 | 1100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
BRCA1 | 1100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
BRP44 | 24515 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
BRWD1 | 12760 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
C11ORF86 | 34442 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
C12ORF48 | 26074 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
C14ORF2 | 1188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
C17ORF67 | 27900 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
C18ORF12 | NA | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
C18ORF54 | 13796 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
C1ORF116 | 28667 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
C1ORF116 | 28667 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
C1ORF21 | 15494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
C1QL3 | 19359 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
C1S | 1247 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
C1S | 1247 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
C21ORF91 | 16459 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
C3ORF18 | 24837 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
C4BPA | 1325 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
C5 | 1331 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
C5 | 1331 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
C8orf37 | 27232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
C8orf37 | 27232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
C9ORF92 | 19054 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CA12 | 1371 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CA12 | 1371 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CA13 | 14914 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CA13 | 14914 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CA2 | 1373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 35229723
|
CA2 | 1373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CA2 | 1373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CA8 | 1382 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CA8 | 1382 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CAB39 | 20292 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CAB39 | 20292 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CABIN1 | 24187 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CABLES2 | 16143 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CACNA1B | 1389 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CACNA1D | 1391 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CACTIN | 29938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CAD | 1424 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CADM1 | 5951 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CADM1 | 5951 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CADM2 | 29849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
CADM3 | 17601 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
CALCOCO2 | 29912 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CAMK1D | 19341 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
CAMK2D | 1462 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CAMK2D | 1462 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CAP1 | 20040 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CAPN1 | 1476 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CAPN5 | 1482 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CAPNS2 | 16371 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CAPRIN1 | 6743 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CARD6 | 16394 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CARD6 | 16394 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CARMN | 42872 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CASKIN1 | 20879 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CASP3 | 1504 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CASP4 | 1505 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CASP4 | 1505 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CASS4 | 15878 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
CASTOR2 | 37073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CASTOR2 | 37073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CASTOR3 | 29954 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CAT | 1516 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
CAT | 1516 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
CATSPER1 | 17116 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CAV1 | 1527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0117 | 25881239
|
CAV2 | 1528 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
CAV2 | 1528 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
CBFA2T3 | 1537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CBX2 | 1552 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CBX8 | 15962 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CCBE1 | 29426 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CCBE1 | 29426 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CCDC144A | 29072 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CCDC144A | 29072 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CCDC144B | 26704 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CCDC144B | 26704 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CCDC144CP | 29073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CCDC144CP | 29073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CCDC198 | 20189 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CCDC198 | 20189 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CCDC22 | 28909 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CCDC34 | 25079 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CCDC34 | 25079 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CCDC43 | 26472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CCDC57 | 27564 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CCDC68 | 24350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CCDC77 | 28203 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CCDC78 | 14153 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CCDC80 | 30649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CCDC80 | 30649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CCDC85A | 29400 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CCDC88C | 19967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CCL20 | 10619 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 35229723
|
CCL20 | 10619 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
CCNA1 | 1577 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CCNA1 | 1577 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CCNA2 | 1578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
CCNA2 | 1578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
CCNA2 | 1578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
CCNB1 | 1579 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
CCND2 | 1583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CCND2 | 1583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CCND3 | 1585 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CCNE1 | 1589 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CCNG2 | 1593 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CCNG2 | 1593 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CCPG1 | 24227 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CCR8 | 1609 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
CCT6B | 1621 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CCT7 | 1622 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CD22 | 1643 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
CD22 | 1643 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
CD274 | 17635 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CD274 | 17635 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CD302 | 30843 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CD302 | 30843 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CD302 | 30843 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CD302 | 30843 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CD36 | 1663 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
CD36 | 1663 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
CD47 | 1682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CD47 | 1682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CD55 | 2665 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CD58 | 1688 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
CD59 | 1689 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CD59 | 1689 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CD68 | 1693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CD74 | 1697 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CD84 | 1704 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
CD9 | 1709 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CD9 | 1709 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CD93 | 15855 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
CD99L2 | 18237 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
CDC20 | 1723 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CDC20 | 1723 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CDC25A | 1725 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CDC25B | 1726 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CDC42EP3 | 16943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CDC42EP3 | 16943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CDCP1 | 24357 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CDCP1 | 24357 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CDH11 | 1750 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
CDH11 | 1750 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
CDH13 | 1753 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CDH13 | 1753 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CDH16 | 1755 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
CDH17 | 1756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
CDH17 | 1756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CDH17 | 1756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CDH2 | 1759 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0085 | 25881239
|
CDH23 | 13733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CDH3 | 1762 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CDH3 | 1762 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CDH6 | 1765 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
CDH6 | 1765 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
CDH6 | 1765 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CDH8 | 1767 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
CDHR1 | 14550 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
CDK11A | 1730 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CDK12 | 24224 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CDK14 | 8883 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CDK14 | 8883 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CDK17 | 8750 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CDK19 | 19338 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CDK2 | 1771 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CDK6 | 1777 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CDKL5 | 11411 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CDKN1A | 1784 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
CDKN2B-AS1 | 34341 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CDKN2B-AS1 | 34341 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CDKN3 | 1791 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CDKN3 | 1791 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CDR1 | 1798 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CDR1 | 1798 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CDRT1 | 14379 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CDRT1 | 14379 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CDRT1 | 14379 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CDRT1 | 14379 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CDS1 | 1800 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CDS1 | 1800 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CDT1 | 24576 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CEACAM6 | 1818 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 35229723
|
CEACAM6 | 1818 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
CEBPB | 1834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CENPA | 1851 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
CENPE | 1856 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CENPE | 1856 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CENPE | 1856 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CENPO | 28152 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CENPV | 29920 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CENPV | 29920 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CEP112 | 28514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CEP112 | 28514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CEP126 | 29264 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CES1 | 1863 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CES1 | 1863 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CFAP20DC | 24763 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CFAP20DC | 24763 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CFAP251 | 28506 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CFAP251 | 28506 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CFL2 | 1875 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
CHAF1B | 1911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CHD4 | 1919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CHD9 | 25701 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CHERP | 16930 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CHGB | 1930 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CHID1 | 28474 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CHML | 1941 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CHMP1A | 8740 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CHN1 | 1943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CHN1 | 1943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CHORDC1 | 14525 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CHPT1 | 17852 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CHPT1 | 17852 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CHRNA5 | 1959 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CHRNA5 | 1959 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CHRNB1 | 1961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CHRNB1 | 1961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CHST12 | 17423 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CHSY1 | 17198 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CHTF18 | 18435 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CIAO3 | 14179 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CIDEC | 24229 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CIT | 1985 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CKMT1A | 31736 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CKMT1A | 31736 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CKMT1B | 1995 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CKMT1B | 1995 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CLCA2 | 2016 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CLCA2 | 2016 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CLCC1 | 29675 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CLCC1 | 29675 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CLDN1 | 2032 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
CLDN10 | 2033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CLDN10 | 2033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
CLDN11 | 8514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CLDN11 | 8514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CLDN12 | 2034 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CLDN18 | 2039 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
CLDN2 | 2041 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CLDN2 | 2041 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
CLDN7 | 2049 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
CLEC4E | 14555 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CLIC1 | 2062 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
CLIC1 | 2062 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
CLIC1 | 2062 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
CLIC1 | 2062 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
CLMN | 19972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CLMN | 19972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CLMP | 24039 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CLMP | 24039 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CLN6 | 2077 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CLSPN | 19715 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CLSTN1 | 17447 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CLSTN1 | 17447 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CLTB | 2091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CMTM7 | 19178 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CMTM8 | 19179 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CNKSR2 | 19701 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CNKSR2 | 19701 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CNN2 | 2156 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CNN2 | 2156 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CNNM1 | 102 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CNNM1 | 102 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CNNM2 | 103 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CNNM4 | 105 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CNNM4 | 105 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CNNM4 | 105 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CNTLN | 23432 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CNTN1 | 2171 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CNTN1 | 2171 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CNTNAP2 | 13830 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CNTNAP3 | 13834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CNTNAP3B | 32035 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CNTNAP3B | 32035 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CNTNAP4 | 18747 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
COA3 | 24990 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
COBLL1 | 23571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
COCH | 2180 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
COCH | 2180 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
COG7 | 18622 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
COL12A1 | 2188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
COL12A1 | 2188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
COL12A1 | 2188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
COL13A1 | 2190 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
COL14A1 | 2191 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
COL16A1 | 2193 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
COL28A1 | 22442 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
COL4A3 | 2204 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
COL5A2 | 2210 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
COL6A1 | 2211 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
COL7A1 | 2214 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
COL7A1 | 2214 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
COMMD10 | 30201 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
COPS7A | 16758 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
COQ4 | 19693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CORO1B | 2253 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CORO2A | 2255 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CORO2A | 2255 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CORO2A | 2255 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
COX6B1 | 2280 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
COX7B | 2291 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CP | 2295 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CP | 2295 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CPA4 | 15740 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
CPE | 2303 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
CPEB1 | 21744 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CPEB4 | 21747 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CPLX2 | 2310 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CPLX2 | 2310 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CPNE4 | 2317 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CPNE4 | 2317 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CPOX | 2321 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CPPED1 | 25632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CPPED1 | 25632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CPPED1 | 25632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CPS1 | 2323 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
CPS1 | 2323 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
CPXM2 | 26977 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
CRABP1 | 2338 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CRABP2 | 2339 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CREB5 | 16844 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CREBL2 | 2350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CREBRF | 24050 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CRH | 2355 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CRIP1 | 2360 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CRIPT | 14312 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CROCCP2 | 28170 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CROT | 2366 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CRYBG1 | 356 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CRYBG1 | 356 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CRYBG2 | 17295 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CRYZ | 2419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CRYZ | 2419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CSAG1 | 24294 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CSGALNACT1 | 24290 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
CSGALNACT1 | 24290 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
CSNK1E | 2453 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CSNK1E | 2453 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CST1 | 2473 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
CSTA | 2481 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CSTA | 2481 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
CTAGE15 | 2481 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CTAGE15 | 2481 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CTAGE4 | 24772 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CTAGE4 | 24772 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CTAGE6 | 28644 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CTAGE6 | 28644 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CTAGE8 | 37294 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CTAGE8 | 37294 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CTAGE9 | 37275 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CTAGE9 | 37275 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CTNNAL1 | 2512 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
CTSB | 2527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
CTSF | 2531 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
CTSK | 2536 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CTSL | 2537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CTSL | 2537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CTTNBP2NL | 25330 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CTTNBP2NL | 25330 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CUTC | 24271 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CXADR | 2559 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CXADR | 2559 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CXCL1 | 4602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
CXCL1 | 4602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
CXCL2 | 4603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
CYB561 | 2571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CYB5A | 2570 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CYB5R1 | 13397 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CYB5R2 | 24376 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CYB5R2 | 24376 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
CYBRD1 | 20797 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CYBRD1 | 20797 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CYFIP2 | 13760 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CYFIP2 | 13760 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
CYP1B1 | 2597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 29416721
|
CYP1B1 | 2597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
CYP24A1 | 2602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CYP24A1 | 2602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CYP3A5 | 2638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CYP3A7 | 2640 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
CYP4F11 | 13265 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CYP4F11 | 13265 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
CYP4F2 | 2645 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
CYP4F3 | 2646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
DAAM1 | 18142 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DAPK1 | 2674 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
DAPK1 | 2674 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
DAPP1 | 16500 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
DAPP1 | 16500 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
DBF4B | 17883 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DCAF11 | 20258 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DCAF11 | 20258 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DCAF12 | 19911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DCAF6 | 30002 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DCDC2 | 18141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
DCDC2 | 18141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
DCLRE1A | 17660 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DDB2 | 2718 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29316740
|
DDC | 2719 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DDX23 | 17347 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DDX55 | 20085 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DDX58 | 19102 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DDX58 | 19102 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DENND11 | 29472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
DENND2B | 11350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DENND5B | 28338 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
DENND5B | 28338 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
DET1 | 25477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
DET1 | 25477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
DEXI | 13267 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DGAT1 | 2843 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DGCR5 | 16757 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DGKA | 2849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DGKA | 2849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DGKD | 2851 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DGKD | 2851 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DGKH | 2854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DGKH | 2854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DHCR24 | 2859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
DHCR24 | 2859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
DHCR24 | 2859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
DHCR7 | 2860 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
DHFR | 2861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
DHFR | 2861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
DHFR | 2861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
DHRS1 | 16445 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DHRS1 | 16445 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DHRS9 | 16888 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
DHX38 | 17211 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
DHX40 | 18018 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DHX40 | 18018 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DICER1-AS1 | 43017 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DIO3OS | 20348 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DIS3L | 28698 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DIS3L | 28698 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DIXDC1 | 23695 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DKK3 | 2893 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
DKK3 | 2893 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
DLG1 | 2900 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DLG1 | 2900 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DLGAP1-AS1 | 31676 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DLX4 | 2917 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DMAC2 | 25496 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DMKN | 25063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
DMKN | 25063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
DMRTC1 | 13910 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DMXL2 | 2938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DMXL2 | 2938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DNA2 | 2939 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
DNAAF11 | 16725 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DNAJC12 | 28908 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
DNAJC12 | 28908 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
DNAJC22 | 25802 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DNAJC3 | 9439 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DNAJC5 | 16235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DND1 | 23799 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DNM1 | 2972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DNM1 | 2972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DOCK10 | 23479 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
DOCK11 | 23483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
DOCK4 | 19192 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DOCK4 | 19192 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DOCK7 | 19190 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DOCK7 | 19190 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DOCK8 | 19191 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
DOCK9 | 14132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DOCK9 | 14132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DOK4 | 19868 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DOK4 | 19868 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DOLK | 23406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DOLK | 23406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DOP1B | 1291 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DOP1B | 1291 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DPP4 | 3009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0085 | 29416721
|
DPP9 | 18648 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DPY19L1 | 22205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DPY19L1 | 22205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DPYSL2 | 3014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
DPYSL2 | 3014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
DPYSL3 | 3015 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DRAP1 | 3019 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DSC2 | 3036 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 29416721
|
DSC2 | 3036 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
DSC2 | 3036 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
DSC3 | 3037 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DSC3 | 3037 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DSE | 21144 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DSE | 21144 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DSEL | 18144 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DSG2 | 3049 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
DSG3 | 3050 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
DSG3 | 3050 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
DSG3 | 3050 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
DSP | 3052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
DSTNP2 | 34546 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DTX2 | 15973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DUS2 | 26014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DUSP1 | 3064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
DUSP1 | 3064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
DUSP16 | 17909 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
DUSP28 | 33237 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DUSP6 | 3072 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
DUSP6 | 3072 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
DUSP7 | 3073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DUSP7 | 3073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
DUXAP9 | 32188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DUXAP9 | 32188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
DYNLL2 | 24596 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
DZIP1 | 20908 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
DZIP3 | 30938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
DZIP3 | 30938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
E2F1 | 3113 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
E2F5 | 3119 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
E2F5 | 3119 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
E2F7 | 23820 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 29316740
|
E2F7 | 23820 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
E2F7 | 23820 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
E2F8 | 24727 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
EAPP | 19312 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
EBF1 | 3126 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
EBF1 | 3126 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
EBP | 3133 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ECH1 | 3149 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ECH1 | 3149 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
EDA | 3157 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
EDA | 3157 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
EDA2R | 17756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
EDEM1 | 18967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EDEM1 | 18967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EDN1 | 3176 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
EDN1 | 3176 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
EDN2 | 3177 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
EDNRA | 3179 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EDNRA | 3179 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EFEMP1 | 3218 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
EFEMP1 | 3218 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
EFNA1 | 3221 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
EFNA1 | 3221 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
EFNA1 | 3221 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
EFNB2 | 3227 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EFNB2 | 3227 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EFTUD2 | 30858 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
EGFR | 3236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
EGFR | 3236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
EGR1 | 3238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
EHBP1 | 29144 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
EHD1 | 3242 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
EHD4 | 3245 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EHF | 3246 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
EHF | 3246 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
EID3 | 32961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
EIF2AK4 | 19687 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EIF2AK4 | 19687 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ELAPOR1 | 29618 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
ELAPOR2 | 21945 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ELAPOR2 | 21945 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ELAVL2 | 3313 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ELK3 | 3325 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ELL2 | 17064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ELL2 | 17064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ELL2 | 17064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ELL2 | 17064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ELMO1 | 16286 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ELMO1 | 16286 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ELOA | 11620 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ELOVL1 | 14418 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ELOVL2 | 14416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
ELOVL2 | 14416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
ELOVL2 | 14416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
ELOVL6 | 15829 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ELOVL6 | 15829 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
EMB | 30465 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EMB | 30465 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EME1 | 24965 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
EML1 | 3330 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
EML1 | 3330 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
EML4 | 1316 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
EML4 | 1316 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
EMP1 | 3333 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
EMP1 | 3333 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
EMX1 | 3340 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ENDOD1 | 29129 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ENDOV | 26640 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ENGASE | 24622 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ENO2 | 3353 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
ENPP1 | 3356 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ENPP1 | 3356 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ENPP5 | 13717 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ENTPD1 | 3363 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
ENTPD3 | 3365 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ENTPD3 | 3365 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
EOGT | 28526 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EOGT | 28526 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EPB41L1 | 3378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
EPB41L1 | 3378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
EPB41L4A-DT | 25643 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
EPDR1 | 17572 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
EPHA7 | 3390 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
EPHB3 | 3394 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29416721
|
EPHB3 | 3394 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29416721
|
EPHX1 | 3401 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
EPHX1 | 3401 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
EPS8 | 3420 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
EPS8L2 | 21296 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ERAP1 | 18173 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ERAP2 | 29499 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ERAP2 | 29499 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ERBB2 | 3430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 34059086
|
ERBB2 | 3430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 34059086
|
ERC2-IT1 | 1229 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ERCC6 | 3438 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ERCC6 | 3438 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ERI2 | 30541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ERICH1 | 27234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ERLEC1 | 25222 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ERO1A | 13280 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
ERO1B | 14355 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ESCO2 | 27230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
ESCO2 | 27230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ESRP1 | 25966 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ESRP1 | 25966 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ESRP2 | 26152 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ESYT1 | 29534 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ETFB | 3482 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ETFB | 3482 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ETFBKMT | 28739 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ETFBKMT | 28739 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ETHE1 | 23287 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ETNK1 | 24649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ETNK1 | 24649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ETS1 | 3488 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ETS1 | 3488 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ETS2 | 3489 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ETV1 | 3490 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
ETV1 | 3490 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
EVA1C | 13239 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
EWSR1 | 3508 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
EWSR1 | 3508 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
EXOC6 | 23196 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
EXOC6 | 23196 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
EXOSC4 | 18189 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
EXT1 | 3512 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
EXTL3 | 3518 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EYA1 | 3519 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EYA1 | 3519 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
EYA3 | 3521 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
F11R | 14685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
F11R | 14685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
F11R | 14685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
F2 | 3535 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
F2R | 3537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
F2RL1 | 3538 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
F2RL1 | 3538 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
F2RL2 | 3539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
F2RL2 | 3539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
F3 | 3541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
F3 | 3541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
F5 | 3542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 35229723
|
F5 | 3542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
F5 | 3542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
F5 | 3542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
F8A1 | 3547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
F8A1 | 3547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
F8A1 | 3547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
F8A2 | 31849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
F8A2 | 31849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
F8A3 | 31850 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
F8A3 | 31850 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FAHD1 | 14169 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
FAM102A | 31419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
FAM102A | 31419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
FAM102A | 31419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
FAM102A | 31419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FAM102A | 31419 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FAM102B | 27637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
FAM102B | 27637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
FAM107B | 23726 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FAM107B | 23726 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FAM117B | 14440 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
FAM126A | 24587 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
FAM136A | 25911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FAM160A1 | 34237 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FAM160A1 | 34237 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FAM161A | 25808 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FAM171B | 29412 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FAM171B | 29412 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FAM172BP | 34336 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FAM3A | 13749 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
FAM3C | 18664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FAM3C | 18664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FAM3C | 18664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FAM3C | 18664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FAM81A | 28379 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FAM83A | 28210 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FAM83A | 28210 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FAM83B | 21357 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
FAM83B | 21357 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
FAM83H | 24797 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
FAM86B1 | 28268 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
FAM86B1 | 28268 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FAM86B1 | 28268 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FAM86C1P | 25561 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FAN1 | 29170 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
FANCB | 3583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FANCF | 3587 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
FAR2 | 25531 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FAR2 | 25531 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FAS | 11920 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
FAS | 11920 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
FAT2 | 3596 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FAT2 | 3596 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FAT3 | 23112 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
FAT3 | 23112 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
FAT4 | 23109 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
FBLN5 | 3602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FBN2 | 3604 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FBXL18 | 21874 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
FBXL20 | 24679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
FBXL20 | 24679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FBXO17 | 18754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FBXO17 | 18754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FBXO2 | 13581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
FBXO41 | 29409 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
FBXW7 | 16712 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FCGBP | 13572 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 35229723
|
FCGBP | 13572 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
FCSK | 29500 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
FDFT1 | 3629 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FDFT1 | 3629 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FDPS | 3631 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
FERMT1 | 15889 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
FERMT1 | 15889 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FERMT1 | 15889 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FERMT2 | 15767 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FES | 3657 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
FEZ1 | 3659 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FEZ1 | 3659 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FGA | 3661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FGA | 3661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FGB | 3662 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FGB | 3662 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FGD4 | 19125 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FGF11 | 3667 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FGF11 | 3667 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FGF2 | 3676 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
FGF2 | 3676 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
FGF5 | 3683 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FGF5 | 3683 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FGFBP1 | 19695 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FGFBP1 | 19695 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FGFR1 | 3688 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
FGFR1 | 3688 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
FGFR2 | 3689 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
FGFR2 | 3689 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
FGFR4 | 3691 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 29316740
|
FGG | 3694 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FGG | 3694 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FGL1 | 3695 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
FGL1 | 3695 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FGL1 | 3695 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FHL2 | 3703 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
FHOD3 | 26178 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FHOD3 | 26178 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FILIP1 | 21015 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FILIP1 | 21015 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FILIP1L | 24589 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FITM2 | 16135 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FJX1 | 17166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FKBP1A | 3711 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
FKRP | 13949 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
FLI1 | 3749 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FLI1 | 3749 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FLOT2 | 3758 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
FLRT2 | 3761 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FLRT2 | 3761 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FLVCR1 | 24682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
FLVCR1 | 24682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FLVCR1 | 24682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FLVCR2 | 20105 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
FMNL1 | 1212 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
FOCAD | 23377 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
FOCAD | 23377 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FOS | 3796 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
FOXK1 | 23480 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
FREM1 | 23399 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
FRMD3 | 24125 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
FRMD4B | 24886 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
FRMD4B | 24886 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
FRMD6 | 19839 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FRMD6 | 19839 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FRYL | 29127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FRYL | 29127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FRYL | 29127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FRYL | 29127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
FSCN1 | 11148 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
FST | 3971 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FST | 3971 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FSTL1 | 3972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FSTL1 | 3972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FTL | 3999 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
FUT11 | 19233 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
FXYD2 | 4026 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
FXYD3 | 4027 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
FZD6 | 4044 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
FZD6 | 4044 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
FZR1 | 24824 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
G0S2 | 30229 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
G0S2 | 30229 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
G6PC3 | 24861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
G6PD | 4057 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
GAB1 | 4066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
GAB1 | 4066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
GABARAPL1 | 4068 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
GABRA5 | 4079 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GABRA5 | 4079 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GABRB3 | 4083 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
GABRB3 | 4083 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GABRB3 | 4083 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GADD45A | 4095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GALC | 4115 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GALM | 24063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
GALM | 24063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
GALM | 24063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
GALNT13 | 23242 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GALNT13 | 23242 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GALNT3 | 4125 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
GALNT3 | 4125 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
GALNT4 | 4126 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GALNT4 | 4126 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GALNT5 | 4127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
GALNT5 | 4127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
GALNT6 | 4128 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
GALNT6 | 4128 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
GALNT6 | 4128 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
GAS2L3 | 27475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
GATM | 4175 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
GATM | 4175 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
GBP1 | 4182 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GBP3 | 4184 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GBP3 | 4184 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GBP3 | 4184 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GBP6 | 25395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GBP6 | 25395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GC | 4187 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
GCA | 15990 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GCLC | 4311 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
GCNT2 | 4204 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GCNT2 | 4204 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GCNT3 | 4205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GCNT3 | 4205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GCNT4 | 17973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GCNT4 | 17973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GDAP1 | 15968 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
GDAP1 | 15968 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GDF15 | 30142 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
GDPGP1 | 34360 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GEM | 4234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GEMIN5 | 20043 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GEMIN6 | 20044 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GFER | 4236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GGA2 | 16064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GGCX | 4247 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GGT8P | 33438 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GGTLC1 | 16437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GID8 | 15857 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GINS1 | 28980 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GINS2 | 24575 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GINS2 | 24575 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GINS2 | 24575 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GINS4 | 28226 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
GJB1 | 4283 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
GJB2 | 4284 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
GJB2 | 4284 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
GJB5 | 4287 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GJB5 | 4287 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GJB6 | 4288 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GJC1 | 4280 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GJC1 | 4280 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GKAP1 | 17496 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GKAP1 | 17496 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GLA | 4296 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GLA | 4296 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GLDC | 4313 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GLDC | 4313 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GLDN | 29514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
GLG1 | 4316 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GLI3 | 4319 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GLI3 | 4319 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GLIPR1 | 17001 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GLIPR1 | 17001 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GLIS3 | 28510 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GLIS3 | 28510 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GLRX | 4330 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
GLT8D2 | 24890 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GLUL | 4341 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GLUL | 4341 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GLUL | 4341 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GLYCTK | 24247 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GM2A | 4367 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GM2A | 4367 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GNA15 | 4383 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GNA15 | 4383 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GNAI2 | 4385 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GNAI2 | 4385 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GNB4 | 20731 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GNE | 23657 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
GNG11 | 4403 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GNG11 | 4403 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GNL3L | 25553 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GOLGA2P2Y | 16479 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GOLGA2P5 | 25315 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
GOLPH3 | 15452 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GOLPH3L | 24882 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GOPC | 17643 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GOSR1 | 4430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GPAT3 | 28157 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GPAT3 | 28157 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GPATCH1 | 24658 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GPC6 | 4454 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GPC6 | 4454 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GPCPD1 | 26957 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GPD1L | 28956 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GPNMB | 4462 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
GPR141 | 19997 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GPR160 | 23693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
GPR20 | 4475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GPR37L1 | 14923 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
GPR87 | 4538 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
GPRC5A | 9836 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
GPRC5B | 13308 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GPRIN3 | 27733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GPRIN3 | 27733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GPSM2 | 29501 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GPSM2 | 29501 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GPX2 | 4554 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
GPX2 | 4554 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
GPX3 | 4555 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
GPX3 | 4555 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
GRAMD1B | 29214 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GRAMD1B | 29214 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GRAMD2B | 24911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
GRAMD2B | 24911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
GRB14 | 4565 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GRB14 | 4565 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GREB1 | 24885 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
GRK5 | 4544 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GRK5 | 4544 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GRN | 4601 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
GSDMC | 7151 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GSDMC | 7151 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
GSR | 4623 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GSR | 4623 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GSTA4 | 4629 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
GSTM2 | 4634 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GSTM4 | 4636 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GSTT2 | 4642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GSTT2 | 4642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GSTT2 | 4642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GSTT2B | 33437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GSTT2B | 33437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GSTT2B | 33437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
GTF3C2 | 4665 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GTPBP1 | 4669 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GUCA1B | 4679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GULP1 | 18649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
GULP1 | 18649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
GYG2 | 4700 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GYG2 | 4700 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
GYG2P1 | 4701 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
GYS1 | 4706 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
H1-1 | 4715 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
H1-1 | 4715 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
H1-3 | 4717 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
H19 | 4713 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
H19 | 4713 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
H2AC17 | 4735 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29316740
|
H2AC21 | 20508 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
H2AC4 | 4734 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
H2BC12 | 13954 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
H2BC9 | 4755 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
H2BC9 | 4755 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
H3C11 | 4771 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HABP2 | 4798 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29416721
|
HACD3 | 24175 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HACD4 | 20920 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HAVCR1 | 17866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
HAVCR1 | 17866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
HBB | 4827 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
HBEGF | 3059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HBEGF | 3059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HCLS1 | 4844 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HCLS1 | 4844 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HDAC1 | 4852 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
HDAC8 | 13315 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
HEATR5A | 20276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HECW1 | 22195 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HEG1 | 29227 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
HELB | 17196 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HEMK1 | 24923 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HEPACAM | 26361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
HEPHL1 | 30477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
HEPHL1 | 30477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
HERC3 | 4876 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HERC3 | 4876 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HERC5 | 24368 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HES1 | 5192 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 34059086
|
HEXA | 4878 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
HEXA-AS1 | 25810 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
HGD | 4892 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HGD | 4892 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HGD | 4892 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HGD | 4892 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HGSNAT | 26527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
HHEX | 4901 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HHEX | 4901 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HHIP | 14866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HHIPL2 | 25842 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HHIPL2 | 25842 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HID1 | 15736 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HILPDA | 28859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
HIP1 | 4913 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HIP1 | 4913 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HIP1 | 4913 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HIP1 | 4913 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HIRIP3 | 4917 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
HIVEP2 | 4921 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HIVEP2 | 4921 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HJURP | 25444 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HK2 | 4923 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HKDC1 | 23302 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HKDC1 | 23302 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HLA-A | 4931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-A | 4931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-A | 4931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-A | 4931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-A | 4931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-A | 4931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-B | 4932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-C | 4933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HLA-C | 4933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HLA-C | 4933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HLA-C | 4933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HLA-C | 4933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HLA-DMA | 4934 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HLA-DMB | 4935 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HLA-DMB | 4935 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HLA-G | 4964 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-G | 4964 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HLA-J | 4967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HLA-J | 4967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HLTF | 11099 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HLTF | 11099 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HM13 | 16435 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HMCN2 | 21293 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
HMGA2 | 5009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
HMGA2 | 5009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
HMGCR | 5006 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
HMGCR | 5006 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
HMGCS1 | 5007 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
HMGCS1 | 5007 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
HMGN2 | 4986 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HMGN5 | 8013 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
HMOX1 | 5013 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
HMOX1 | 5013 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
HMOX1 | 5013 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
HMOX2 | 5014 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HNF1A-AS1 | 26785 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HNF1A-AS1 | 26785 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HNF1B | 11630 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HNF1B | 11630 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HNF4G | 5026 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HNRNPD | 5036 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HOOK2 | 19885 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
HOOK3 | 23576 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
HORMAD1 | 25245 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HORMAD1 | 25245 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HOXA-AS3 | 43748 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
HOXB6 | 5117 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HOXB6 | 5117 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HOXB6 | 5117 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HOXB-AS3 | 40283 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
HPGD | 5154 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
HPGD | 5154 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
HPSE | 5164 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
HRAS | 5173 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HRAS | 5173 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HRAS | 5173 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HRSP12 | 16897 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HSD11B2 | 5209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
HSD17B11 | 22960 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HSD17B11 | 22960 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HSPA1A | 5232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
HSPA1A | 5232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
HSPA1B | 5233 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
HSPA2 | 5235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
HSPA4L | 17041 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
HSPB1 | 5246 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
HSPE1 | 5269 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
HSPG2 | 5273 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
HTATIP2 | 16637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HTATIP2 | 16637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HTR1D | 5289 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
HUWE1 | 30892 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
HYKK | 34403 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
HYKK | 34403 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ID2 | 5361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
ID2 | 5361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
ID3 | 5362 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ID3 | 5362 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
IDH1-AS1 | 40292 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
IER3 | 5392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
IER3 | 5392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
IER3 | 5392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
IER3 | 5392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
IER3 | 5392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
IER3 | 5392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
IFFO2 | 27006 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IFI16 | 5395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
IFI16 | 5395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
IFI30 | 5398 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
IFI35 | 5399 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
IFI44 | 16938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
IFI44 | 16938 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
IFITM10 | 40022 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
IFITM3 | 5414 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
IFITM3 | 5414 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
IFNE | 18163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
IFNGR2 | 5440 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IFNL2 | 18364 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
IFT20 | 30989 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
IFT80 | 29262 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
IFT81 | 14313 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
IFT81 | 14313 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
IGF2 | 5466 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
IGF2BP1 | 28866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
IGF2BP1 | 28866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
IGF2BP1 | 28866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
IGF2BP1 | 28866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
IGF2BP2 | 28867 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
IGF2BP2 | 28867 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
IGF2BP3 | 28868 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 34059086
|
IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 34059086
|
IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 34059086
|
IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 34059086
|
IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0095 | 25881239
|
IGFBP3 | 5472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0095 | 25881239
|
IGFBP5 | 5474 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
IGFBP7 | 5476 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
IGFBP7 | 5476 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
IGIP | 33847 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
IGLL1 | 5870 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
IL16 | 5980 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
IL16 | 5980 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
IL17RA | 5985 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
IL1A | 5991 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
IL1A | 5991 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
IL1B | 5992 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 35229723
|
IL1B | 5992 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 29416721
|
IL1B | 5992 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
IL1B | 5992 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
IL1R1 | 5993 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
IL1R1 | 5993 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
IL1RAP | 5995 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IL1RAP | 5995 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IL1RL1 | 5998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IL1RL1 | 5998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IL1RN | 6000 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
IL1RN | 6000 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
IL20RB | 6004 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IL20RB | 6004 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IL31RA | 18969 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IL31RA | 18969 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IL4R | 6015 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IL6R | 6019 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 18034892
|
IL7R | 6024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
IL7R | 6024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
IMPA2 | 6051 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29316740
|
INA | 6057 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
INA | 6057 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
INAVA | 25599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
INF2 | 23791 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ING3 | 14587 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
INPP4B | 6075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
INPP4B | 6075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
INPP4B | 6075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
INPP5D | 6079 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
INPP5D | 6079 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
INPP5E | 21474 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
INPP5F | 17054 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
INSIG1 | 6083 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
INSIG1 | 6083 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
INSIG2 | 20452 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
INS-IGF2 | 33527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
INS-IGF2 | 33527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
INSL4 | 6087 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
INSL4 | 6087 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
INTS2 | 29241 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
INTS9 | 25592 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
IQCA1 | 26195 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
IQCA1 | 26195 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
IQCJ-SCHIP1 | 38842 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
IQGAP2 | 6111 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
IQGAP2 | 6111 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
IQSEC2 | 29059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
IRAG2 | 6690 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IRAIN | 50365 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
IRAK3 | 17020 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IRAK3 | 17020 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
IREB2 | 6115 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
IRF6 | 6121 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
IRF6 | 6121 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
IRX5 | 14361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ISL1 | 6132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ISL1 | 6132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ITGA1 | 6134 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
ITGA10 | 6135 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
ITGA11 | 6136 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
ITGA2 | 6137 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0106 | 25881239
|
ITGA2 | 6137 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0106 | 25881239
|
ITGA2B | 6138 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
ITGA3 | 6139 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ITGA3 | 6139 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ITGA5 | 6141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ITGA5 | 6141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ITGA6 | 6142 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0265 | 25881239
|
ITGA6 | 6142 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0265 | 25881239
|
ITGAD | 6146 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
ITGAL | 6148 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
ITGAX | 6152 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
ITGB2 | 6155 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
ITGB2 | 6155 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
ITGB4 | 6158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 29416721
|
ITGB4 | 6158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0074 | 29416721
|
ITGB4 | 6158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
ITGB4 | 6158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
ITGB5 | 6160 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ITGB5 | 6160 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
ITGB6 | 6161 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
ITGB6 | 6161 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
ITGB8 | 6163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 29416721
|
ITGB8 | 6163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
ITGB8 | 6163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
ITGBL1 | 6164 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ITGBL1 | 6164 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ITLN1 | 18259 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ITPR3 | 6182 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ITPR3 | 6182 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
JADE1 | 30027 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
JADE1 | 30027 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
JADE2 | 22984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
JAG1 | 6188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0117 | 25881239
|
JAG1 | 6188 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0117 | 25881239
|
JCAD | 29283 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
JMY | 28916 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
JPH1 | 14201 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
JPT1 | 14569 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
JPT2 | 14137 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
KAAG1 | 21031 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
KANK3 | 24796 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
KAT2B | 8638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
KAT2B | 8638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
KATNAL1 | 28361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
KATNB1 | 6217 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
KBTBD11-OT1 | 49147 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
KCNC4 | 6236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
KCNJ15 | 6261 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
KCNJ15 | 6261 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
KCNMA1 | 6284 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
KCNQ5 | 6299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
KCNQ5 | 6299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
KCP | 17585 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
KCTD14 | 23295 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
KCTD14 | 23295 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
KCTD21 | 27452 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
KEAP1 | 23177 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
KIAA0040 | 28950 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
KIAA0040 | 28950 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
KIAA0319 | 21580 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
KIAA0319 | 21580 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
KIAA1217 | 25428 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
KIAA1217 | 25428 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
KIAA1614 | 29327 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
KIF13B | 14405 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
KIF18A | 29441 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
KIF18A | 29441 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
KIF27 | 18632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
KIF27 | 18632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
KIRREL1 | 15734 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
KIRREL1 | 15734 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
KLF5 | 6349 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
KLF6 | 2235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
KLF6 | 2235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
KLF6 | 2235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
KLF7 | 6350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
KLF7 | 6350 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
KLHDC2 | 20231 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
KLHDC4 | 25272 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
KLHL15 | 29347 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
KLHL36 | 17844 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
KMT2E | 18541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
KNG1 | 6383 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
KNOP1 | 34404 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
KRR1 | 5176 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
KRR1 | 5176 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
KRT14 | 6416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
KRT14 | 6416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
KRT15 | 6421 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
KRT15 | 6421 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
KRT17 | 6427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
KRT17 | 6427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
KRT17 | 6427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
KRT17 | 6427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
KRT17 | 6427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
KRT17 | 6427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
KRT18 | 6430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 25881239
|
KRT18 | 6430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 25881239
|
KRT18 | 6430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 25881239
|
KRT18 | 6430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 25881239
|
KRT19 | 6436 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
KRT4 | 6441 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 18034892
|
KRT5 | 6442 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
KRT5 | 6442 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
KRT6A | 6443 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
KRT6A | 6443 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
KRT6A | 6443 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
KRT6B | 6444 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
KRT6B | 6444 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
KRT6B | 6444 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
KRT6C | 20406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
KRT7 | 6445 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
KRT81 | 6458 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
KRT81 | 6458 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
KRT81 | 6458 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
KRTAP10-10 | 22972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
KRTAP1-3 | 16771 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
KRTAP1-4 | 18904 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
KRTAP4-1 | 18907 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
KYAT3 | 33238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
KYNU | 6469 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
KYNU | 6469 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
LACTB2 | 18512 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
LACTB2 | 18512 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
LACTB2 | 18512 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
LAD1 | 6472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
LAMA3 | 6483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
LAMA3 | 6483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
LAMA3 | 6483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
LAMA5 | 6485 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LAMB3 | 6490 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 29416721
|
LAMB3 | 6490 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
LAMB3 | 6490 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
LAMC2 | 6493 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
LAMC2 | 6493 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
LAMC2 | 6493 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
LAPTM4B | 13646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
LAPTM4B | 13646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
LAPTM5 | 29612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
LAPTM5 | 29612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
LARS2 | 17095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LCLAT1 | 26756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
LCLAT1 | 26756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LDAH | 26145 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
LDLR | 6547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
LDLR | 6547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
LENG9 | 16306 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LETR1 | 49597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LGALS1 | 6561 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
LGALS3BP | 6564 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29416721
|
LGR4 | 13299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
LGR4 | 13299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
LGR6 | 19719 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 35229723
|
LGSN | 21016 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LGSN | 21016 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LHFP | 6586 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LHFP | 6586 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LIFR | 6597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LIFR | 6597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LIMA1 | 24636 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
LIMA1 | 24636 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
LIMK2 | 6614 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LIN7A | 17787 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LIN7A | 17787 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LINC00265 | 28019 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC00294 | 27456 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC00523 | 20117 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC00540 | 43673 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC00672 | 44353 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC00674 | 44355 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC00842 | 44989 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC00963 | 48716 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC00963 | 48716 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC01000 | 38541 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC01433 | 50746 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC01475 | 51113 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC01535 | 51282 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LINC02908 | 31426 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LIPG | 6623 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LIPG | 6623 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LIPH | 18483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LIPH | 18483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LMAN1L | 6632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LMCD1 | 6633 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
LMLN | 15991 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
LMNB1 | 6637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
LMO2 | 6642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LMO2 | 6642 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LNCAROD | 50913 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LNX2 | 20421 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LNX2 | 20421 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LOC728392 | NA | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
LONP2 | 20598 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
LONRF2 | 24788 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LONRF2 | 24788 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LONRF3 | 21152 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
LOX | 6664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 34059086
|
LOXL2 | 6666 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
LPA | 6667 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LPAR1 | 3166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
LPAR1 | 3166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
LPAR3 | 14298 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LPAR3 | 14298 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LPCAT2 | 26032 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
LPCAT2 | 26032 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
LPCAT2 | 26032 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LPCAT4 | 30059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LPP | 6679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LPXN | 14061 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
LPXN | 14061 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
LRBA | 1742 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LRCH1 | 20309 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
LRFN1 | 29290 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LRIG1 | 17360 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
LRIG1 | 17360 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
LRIG1 | 17360 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
LRIG1 | 17360 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
LRIG3 | 30991 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LRP6 | 6698 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LRP6 | 6698 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LRPPRC | 15714 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0064 | 18034892
|
LRR1 | 19742 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
LRRC23 | 19138 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LRRC37A2 | 32404 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
LRRC37A3 | 32427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LRRC37A4P | 25479 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
LRRC37B | 29070 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
LRRC6 | 16725 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
LRRC8A | 19027 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
LRRC8C | 25075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LRRC8C | 25075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LRRK2 | 18618 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
LRRK2 | 18618 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
LRRN2 | 16914 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
LSAMP | 6705 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
LSAMP | 6705 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
LTBP2 | 6715 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
LUCAT1 | 48498 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
LUZP1 | 14985 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
LUZP1 | 14985 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
LXN | 13347 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
LXN | 13347 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
LY75 | 6729 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LY75 | 6729 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
LYNX1 | 29604 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MACsIR | 25052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MACsIR | 25052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MADD | 6766 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MAGI1 | 946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
MAGI1 | 946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
MAL2 | 13634 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
MALL | 6818 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MALL | 6818 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MAML2 | 16259 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MAML3 | 16272 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MAML3 | 16272 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MANF | 15461 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MANSC1 | 25505 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MAOA | 6833 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MAOA | 6833 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MAP1B | 6836 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MAP1B | 6836 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MAP1LC3B2 | 34390 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MAP2 | 6839 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MAP2K5 | 6845 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MAP2K6 | 6846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MAP2K6 | 6846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MAP3K14 | 6853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
MAP3K14-AS1 | 44359 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MAP3K2 | 6854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
MAP3K20 | 17797 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
MAP3K21 | 29798 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MAP3K5 | 6857 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
MAP7D2 | 25899 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MAP7D2 | 25899 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MAPK13 | 6875 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MAPK13 | 6875 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MAPK3 | 6877 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
MAPK8IP2 | 6883 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MAPKAPK3 | 6888 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
MAPKAPK3 | 6888 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MAPKAPK5-AS1 | 24091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MARK1 | 6896 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MARK1 | 6896 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MARS1 | 6898 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MARVELD2 | 26401 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MAT2A | 6904 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
MATN2 | 6908 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MATN2 | 6908 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MBD2 | 6917 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
MBNL3 | 20564 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MBOAT2 | 25193 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MBOAT2 | 25193 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MBTPS2 | 15455 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MBTPS2 | 15455 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MCAM | 6934 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
MCAM | 6934 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
MCC | 6935 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MCC | 6935 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MCM6 | 6949 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MCM8 | 16147 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MCPH1 | 6954 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
MCTP2 | 25636 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MCTP2 | 25636 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MDM4 | 6974 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ME1 | 6983 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
MED13L | 22962 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MED15 | 14248 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MEGF8 | 3233 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MEGF9 | 3234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MEGF9 | 3234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MEIOC | 26670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MEIOC | 26670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MEIS1 | 7000 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MEIS1 | 7000 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MEIS3P1 | 7002 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MEIS3P2 | 17638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MEST | 7028 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
METTL13 | 24248 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
METTL6 | 28343 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
METTL7B | 28276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
METTL7B | 28276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MFAP5 | 29673 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MFAP5 | 29673 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MFF | 24858 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MFN2 | 16877 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MFSD10 | 16894 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MFSD2A | 25897 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MFSD2A | 25897 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MFSD3 | 25157 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MGAT1 | 7044 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MGAT5 | 7049 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MGLL | 17038 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
MGST2 | 7063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
MGST2 | 7063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
MGST3 | 7064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
MIA2 | 18432 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MICAL2 | 24693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MICAL2 | 24693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MICALCL | 24693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MICALCL | 24693 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MICU1 | 1530 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MID1 | 7095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MID1 | 7095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MIEN1 | 28230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
MIF | 7097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
MIR101-1 | 31488 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 31692042
|
MIR129-1 | 31512 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 31692042
|
MIR17HG | 23564 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MIR181A1 | 31590 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 31692042
|
MIR198 | 31570 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MIR198 | 31570 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MIR200A | 31578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 33959615
|
MIR205 | 31583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 31692042
|
MIR205 | 31583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MIR205 | 31583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MIR208A | 31585 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 33959615
|
MIR20B | 32024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0042 | 22301433
|
MIR221 | 31601 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0053 | 33959615
|
MIR222 | 31602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 33959615
|
MIR224 | 31604 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0042 | 22301433
|
MIR27A | 31613 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 31692042
|
MIR27A | 31613 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0053 | 22301433
|
MIR27B | 31614 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0021 | 22301433
|
MIR29B1 | 31619 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0064 | 22301433
|
MIR29B2 | 31620 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 31692042
|
MIR29C | 31621 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 31692042
|
MIR30B | 31625 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 31692042
|
MIR30B | 31625 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0053 | 31692042
|
MIR30B | 31625 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0053 | 22301433
|
MIR30C2 | 31627 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 31692042
|
MIR30D | 31628 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 31692042
|
MIR30E | 31629 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0032 | 22301433
|
MIR34C | 31637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 33959615
|
MIR501 | 32135 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 33959615
|
MIR504 | 32139 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 33959615
|
MIR622 | 32878 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MIR622 | 32878 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MIR675 | 33351 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MIR675 | 33351 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MIR940 | 33683 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
MIRLET7A1 | 31476 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0032 | 22301433
|
MIRLET7D | 31481 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0021 | 22301433
|
MIRLET7F2 | 31484 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Down | 0.04 | 0.0021 | 22301433
|
MLLT3 | 7136 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
MLLT3 | 7136 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MLLT3 | 7136 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MLPH | 29643 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MLXIP | 17055 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
MLYCD | 7150 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MMAA | 18871 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MMD | 7153 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MMD | 7153 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MMP1 | 7155 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MMP1 | 7155 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MMP10 | 7156 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MMP10 | 7156 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MMP14 | 7160 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 35229723
|
MMP14 | 7160 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MMP14 | 7160 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MMP2 | 7166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MMP24-AS1 | NA | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MMP25-AS1 | 51372 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MMP7 | 7174 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 35229723
|
MNS1 | 29636 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MOB3B | 23825 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MORC3 | 23572 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MORC3 | 23572 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MORC4 | 23485 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MORC4 | 23485 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MORC4 | 23485 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MORC4 | 23485 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MOSPD3 | 25078 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MOSPD3 | 25078 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MPC1 | 21606 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MPI | 7216 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
MPP1 | 7219 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MPZL2 | 3496 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
MPZL2 | 3496 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
MPZL3 | 27279 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
MREG | 25478 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MROH1 | 26958 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MROH1 | 26958 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MROH6 | 27814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MRPL12 | 10378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
MRPL33 | 14487 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MRPL38 | 14033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MRPL4 | 14276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MRPL50 | 16654 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MRPS35 | 16635 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MSH3 | 7326 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MSH3 | 7326 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MSH3 | 7326 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MSH3 | 7326 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MSH5 | 7328 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MSL3P1 | 17837 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MSMO1 | 10545 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MSMO1 | 10545 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MST1 | 7380 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 35229723
|
MST1R | 7381 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MST1R | 7381 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MT1DP | 7396 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MT1DP | 7396 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MT1E | 7397 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MT1E | 7397 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MT1F | 7398 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MT1F | 7398 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MT1G | 7399 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MT1G | 7399 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MT1L | 7404 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MT1L | 7404 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MT1P3 | 16120 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MT1P3 | 16120 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
MT1X | 7405 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
MT1X | 7405 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
MT1X | 7405 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
MT2A | 7406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MT2A | 7406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MT2A | 7406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MT2A | 7406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MT2A | 7406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MT2A | 7406 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MTAP | 7413 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MTAP | 7413 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MTMR10 | 25999 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MTMR9 | 14596 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MTSS1 | 20443 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
MTSS1 | 20443 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
MTUS1 | 29789 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MTUS1 | 29789 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MUC13 | 7511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
MUC13 | 7511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
MUC13 | 7511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
MUC5AC | 7515 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
MUC5B | 7516 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
MUC5B | 7516 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
MYBBP1A | 7546 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
MYEF2 | 17940 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MYEF2 | 17940 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
MYEOV | 7563 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MYEOV | 7563 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MYH10 | 7568 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
MYLK | 7590 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
MYLK2 | 16243 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
MYO1D | 7598 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MYO1D | 7598 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
MYO1E | 7599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MYO1E | 7599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MYO6 | 7605 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
MYO9A | 7608 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
MYOCD | 16067 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MYOCD | 16067 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
MYZAP | 43444 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
NABP1 | 26232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
NABP1 | 26232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
NAP1L2 | 7638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NAP1L2 | 7638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NAPA-AS1 | 44118 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NARG2 | 29885 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NARG2 | 29885 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NAV1 | 15989 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NAV1 | 15989 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NAV3 | 15998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
NAV3 | 15998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
NCAPD2 | 24305 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NCEH1 | 29260 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
NCF2 | 7661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
NCOA1 | 7668 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NCOA1 | 7668 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NCOA2 | 7669 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NCOA3 | 7670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NCOA3 | 7670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NCOA7 | 21081 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NCOR1 | 7672 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NCOR1P1 | 16724 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NCRNA00250 | NA | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NDFIP2 | 18537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
NDRG1 | 7679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
NDRG1 | 7679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
NDRG2 | 14460 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NDST1 | 7680 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NECTIN1 | 9706 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NECTIN1 | 9706 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NEDD9 | 7733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
NEDD9 | 7733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
NEFM | 7734 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NEIL3 | 24573 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NEK1 | 7744 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NEK1 | 7744 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NEK2 | 7745 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NELFB | 24324 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NELL2 | 7751 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
NEO1 | 7754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NEO1 | 7754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NEURL4 | 34410 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
NEXN | 29557 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NF2 | 7773 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
NFAT5 | 7774 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NFATC2 | 7776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NFIC | 7786 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NFKB1 | 7794 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
NFKB1 | 7794 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
NFKBIZ | 29805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
NFKBIZ | 29805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
NFRKB | 7802 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NFS1 | 15910 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NFS1 | 15910 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NGEF | 7807 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NGEF | 7807 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NHSL1 | 21021 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NIBAN1 | 16784 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
NICN1 | 18317 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NINL | 29163 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NIPAL1 | 27194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
NIPAL1 | 27194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
NIPAL2 | 25854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
NIPAL2 | 25854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
NIPAL3 | 25233 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NIPAL4 | 28018 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NIPAL4 | 28018 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NIPSNAP1 | 7827 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
NIPSNAP1 | 7827 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
NKAP | 29873 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NKD1 | 17045 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NKRF | 19374 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NLN | 16058 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
NLRP1 | 14374 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NLRP1 | 14374 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NLRP2 | 22948 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NLRP2 | 22948 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NME4 | 7852 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NME4 | 7852 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NME5 | 7853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NME5 | 7853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NMI | 7854 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NMNAT1 | 17877 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NNMT | 7861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
NNMT | 7861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
NOC4L | 28461 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NOD2 | 5331 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NOP53 | 4333 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29316740
|
NOP9 | 19826 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NOSTRIN | 20203 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NOSTRIN | 20203 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NOXA1 | 10668 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 35229723
|
NPAS2 | 7895 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NPAS2 | 7895 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NPC1 | 7897 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
NPC1 | 7897 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
NPC2 | 14537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NPC2 | 14537 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NPEPL1 | 16244 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NPR3 | 7945 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NPR3 | 7945 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NPR3 | 7945 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NPR3 | 7945 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NPW | 30509 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
NPY4R | 9329 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NPY4R | 9329 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NQO1 | 2874 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
NQO1 | 2874 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
NQO2 | 7856 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NR0B1 | 7960 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NR0B1 | 7960 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 18034892
|
NR1D1 | 7962 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
NR1D1 | 7962 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NR1D1 | 7962 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NR2E3 | 7974 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NR4A2 | 7981 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
NR4A3 | 7982 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NR5A2 | 7984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
NR5A2 | 7984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
NRAD1 | 26981 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
NRCAM | 7994 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NRCAM | 7994 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NREP | 16834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NRG4 | 29862 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NRG4 | 29862 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NRSN2 | 16229 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NT5C2 | 8022 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NT5DC2 | 25717 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NT5E | 8021 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 25881239
|
NT5E | 8021 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0095 | 25881239
|
NTM | 17941 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NTM | 17941 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NTN1 | 8029 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
NTN4 | 13658 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
NTRK3 | 8033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
NTRK3 | 8033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
NTRK3 | 8033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
NTRK3 | 8033 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
NTS | 8038 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 35229723
|
NTS | 8038 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
NTS | 8038 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
NUDT11 | 18011 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
NUDT14 | 20141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NUDT6 | 8053 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NUDT6 | 8053 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NUDT7 | 8054 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
NUFIP1 | 8057 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NUP210 | 30052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NUP210 | 30052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
NUP50-DT | 50502 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
NUP62CL | 25960 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
NUP62CL | 25960 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
OAS1 | 8086 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
OAS1 | 8086 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
OAS2 | 8087 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
OAT | 8091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
OAT | 8091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
OCIAD2 | 28685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
OCIAD2 | 28685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
OCIAD2 | 28685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
OCIAD2 | 28685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ODF2 | 8114 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ODF2L | 29225 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ODR4 | 24299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29316740
|
OGDH | 8124 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ONECUT1 | 8138 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
OPTN | 1941 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
OR2A4 | 14729 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
OR2A4 | 14729 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
OR2A7 | 8234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
OR2A7 | 8234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
OR2A7 | 8234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
OR2A7 | 8234 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
OR7E156P | 31311 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
OR8B8 | 8477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ORAI3 | 28185 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
OSBPL10 | 16037 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
OSGEPL1-AS1 | 41009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
OSGIN2 | 1355 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
OSGIN2 | 1355 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
OSTF1 | 8510 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
OSTF1 | 8510 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
OVOL2 | 15804 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
OVOS2 | NA | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
OXCT1 | 8527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
OXCT1 | 8527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
P2RX4 | 8535 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
P3H2 | 19317 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
P3H2 | 19317 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
P4HA1 | 8546 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
P4HA2 | 8547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
P4HA2 | 8547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PABPC3 | 8556 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PABPC4 | 8547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PACS1 | 30032 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PAFAH1B2 | 8575 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
PAK2 | 8591 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PAK3 | 8592 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PAK3 | 8592 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PALMD | 15846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
PALMD | 15846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
PANX1 | 8599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PANX1 | 8599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PAPPA | 8602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PAPPA | 8602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PAPPA | 8602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PAPSS1 | 8603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PAPSS2 | 8604 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PAPSS2 | 8604 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PAQR4 | 26386 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PAQR5 | 29645 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PAQR5 | 29645 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PARD3 | 29645 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PARD6B | 16245 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PARM1 | 16245 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PARP14 | 29232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PATZ1 | 14652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PAXIP1-DT | 27328 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PBX1 | 8632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
PBX1 | 8632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
PBX1 | 8632 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
PCBD1 | 8646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PCBD1 | 8646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PCBP2 | 8648 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PCDH9 | 8661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PCDH9 | 8661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PCDHA1 | 8663 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
PCDHA1 | 8663 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
PCDHA4 | 8670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PCDHB5 | 8690 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PCDHB5 | 8690 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PCDHGA9 | 8707 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
PCDHGC4 | 8717 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
PCED1A | 16212 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PCF11 | 30097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PCLAF | 28961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PCLAF | 28961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PCOLCE2 | 8739 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PCOLCE2 | 8739 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PCYT1A | 8754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PDCD1LG2 | 18731 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PDCD1LG2 | 18731 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PDCD2L | 28194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PDE10A | 8772 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PDE10A | 8772 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PDE1C | 8776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PDE1C | 8776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PDE3A | 8778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PDE3A | 8778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PDE3B | 8779 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PDE4B | 8781 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PDE4B | 8781 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PDE4D | 8783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
PDE4D | 8783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
PDE4D | 8783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
PDE4DIP | 15580 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PDE5A | 8784 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
PDE7B | 8792 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PDE7B | 8792 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PDE8A | 8793 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PDE8A | 8793 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PDE8B | 8794 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PDE8B | 8794 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PDGFC | 8801 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PDGFC | 8801 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PDGFD | 30620 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PDGFD | 30620 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PDGFRL | 8805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PDGFRL | 8805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PDK1 | 8809 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
PDK1 | 8809 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
PDK2 | 8810 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PDK4 | 8812 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PDK4 | 8812 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PDP1 | 9279 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PDP1 | 9279 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PDPK1 | 8816 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
PDPN | 29602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
PDPN | 29602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PDPN | 29602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PEA15 | 8822 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PEAK1 | 29431 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PECAM1 | 8823 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
PECR | 18281 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PECR | 18281 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PEG10 | 14005 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PEG10 | 14005 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PELI1 | 8827 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PELI1 | 8827 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PELI2 | 8828 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PELO | 8829 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
PEPD | 8840 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PER2 | 8846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PERP | 17637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PEX3 | 8858 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PFKFB3 | 8874 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PGBD3 | 19400 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PGBD3 | 19400 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PGD | 8891 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
PGD | 8891 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
PGD | 8891 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
PGM2 | 8906 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PGM2 | 8906 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PGS1 | 30029 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PHACTR2 | 20956 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PHF11 | 17024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PHF16 | 22982 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PHF21A | 24156 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PHF21B | 25161 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PHLDA1 | 8933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
PHLDA1 | 8933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
PHOSPHO1 | 16815 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PHTF1 | 8939 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PHYH | 8940 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PI3 | 8947 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
PI4K2B | 18215 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PI4KA | 8983 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PIGM | 18858 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PIGU | 15791 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PIK3CD | 8977 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PILRA | 20396 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PIP | 8993 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PIP4K2B | 8998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PIR | 30048 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PIR | 30048 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PJVK | 29502 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PKDCC | 25123 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PKP1 | 9023 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PKP2 | 9024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
PKP2 | 9024 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
PKP4 | 9026 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PLA2G4A | 9035 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
PLA2G4A | 9035 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PLA2G4A | 9035 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PLA2R1 | 9042 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PLAAT3 | 17825 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PLAAT3 | 17825 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PLAT | 9051 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
PLAU | 9052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
PLAU | 9052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
PLAU | 9052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
PLBD1 | 26215 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
PLCB1 | 15917 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PLCB3 | 9056 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PLCB4 | 9059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PLCE1 | 17175 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PLCE1 | 17175 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PLCH1 | 29185 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PLCH1 | 29185 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PLD1 | 9067 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PLD1 | 9067 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PLD5 | 26879 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PLD5 | 26879 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PLEK2 | 19238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PLEK2 | 19238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PLEKHH2 | 30506 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PLIN2 | 248 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 25881239
|
PLOD1 | 9081 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
PLPP1 | 9228 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PLPPR1 | 25993 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PLS3-AS1 | 50343 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PLSCR3 | 16495 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PLSCR3 | 16495 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PLSCR4 | 16497 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PLXNA1 | 9099 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PLXNA1 | 9099 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PLXNA2 | 9100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PLXNA2 | 9100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PLXNA2 | 9100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PLXNC1 | 9106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
PMP22 | 9118 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PMP22 | 9118 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PNMA8A | 25578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PNPLA2 | 30802 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PNRC2 | 23158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PNRC2 | 23158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
POC1B | 30836 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
POC1B | 30836 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PODXL | 9171 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
POF1B | 13711 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
POF1B | 13711 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
POLA1 | 9173 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
POLA2 | 30073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
POLD1 | 9175 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
POLD2 | 9176 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
POLD4 | 14106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
POLH | 9181 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
POLH | 9181 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
POLM | 9185 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
POLQ | 9186 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
POLR1A | 17264 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
POLR1D | 20422 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
POLR1G | 24219 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
POLR2C | 9189 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
POLR2E | 9192 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
POLR2F | 9193 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
POLR2G | 9194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
POLR2L | 9199 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PON2 | 9205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PON2 | 9205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PON3 | 9206 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PON3 | 9206 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
POP1 | 30129 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PORCN | 17652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PORCN | 17652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PPARD | 9235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PPARD | 9235 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PPARG | 9236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PPARG | 9236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PPFIBP2 | 9250 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PPIEL | 33195 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PPIL6 | 21557 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PPM1B | 9276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PPM1B | 9276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PPM1B | 9276 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PPME1 | 30178 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PPP1R10 | 9284 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PPP1R13L | 18838 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PPP1R14A | 14871 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PPP1R18 | 29413 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PPP1R18 | 29413 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PPP1R21 | 30595 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PPP1R9A | 14946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PPP2R2A | 9304 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PPP2R2C | 9306 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PPP2R2C | 9306 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PPP2R3A | 9307 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PPP2R3A | 9307 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PPP4R1 | 9320 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PPP4R1 | 9320 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PPP4R4 | 23788 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PPP4R4 | 23788 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PQLC2 | 26001 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PRAME | 9336 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PRAME | 9336 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PRDX1 | 9352 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
PREP | 9358 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PREP | 9358 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PRG4 | 9364 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PRIM1 | 9369 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PRKAA2 | 9377 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PRKAR1B | 9390 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PRKAR2B | 9392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PRKAR2B | 9392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PRKCA | 9393 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
PRKCA | 9393 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
PRKCE | 9401 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PRKD1 | 9407 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PRKD1 | 9407 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PRKDC | 9413 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
PRMT6 | 18241 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PRMT6 | 18241 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PROS1 | 9456 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PROS1 | 9456 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PROS1 | 9456 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PROS1 | 9456 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PRPS1 | 9462 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PRR11 | 25619 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
PRR12 | 29217 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PRR14 | 28458 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PRSS12 | 9477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PRSS12 | 9477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PRSS2 | 9483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PRSS2 | 9483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PRSS2 | 9483 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PRSS27 | 15475 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PRSS3P2 | 43788 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PRTFDC1 | 23333 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
PRTFDC1 | 23333 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
PRTG | 26373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PRTG | 26373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PSIP1 | 9527 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PSMC4 | 9551 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PSMC4 | 9551 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PSMD2 | 9559 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PSME3 | 9570 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PSMF1 | 9571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PSPH | 9577 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PSPH | 9577 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PSTPIP2 | 9581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PSTPIP2 | 9581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PTAFR | 9582 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PTAFR | 9582 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PTCH1 | 9585 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PTCH1 | 9585 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PTER | 9590 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PTGES3L-AARSD1 | 43946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PTGES3L-AARSD1 | 43946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PTGFRN | 9601 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PTGFRN | 9601 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PTGR1 | 18429 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PTGR1 | 18429 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PTGR2 | 20149 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PTPN13 | 9646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PTPN13 | 9646 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PTPN14 | 9647 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PTPN14 | 9647 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PTPN18 | 9649 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PTPRD | 9668 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
PTPRE | 9669 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PTPRE | 9669 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
PTPRG | 9671 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PTPRG | 9671 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PTPRJ | 9673 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PTPRJ | 9673 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PTPRJ | 9673 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
PTPRK | 9674 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PTPRK | 9674 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
PTPRM | 9675 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PTPRM | 9675 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
PTPRZ1 | 9685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PTPRZ1 | 9685 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
PVR | 9705 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PVRIG | 32190 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
PVT1 | 9709 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
PXDN | 14966 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
PXDN | 14966 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
PYGO1 | 30256 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
PYGO1 | 30256 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
QPCT | 9753 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
QSOX1 | 9756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
QSOX1 | 9756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
R3HDM2 | 29167 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RAB11FIP1 | 30265 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
RAB11FIP3 | 17224 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RAB15 | 20150 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RAB15 | 20150 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RAB31 | 9771 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
RAB31 | 9771 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
RAB37 | 30268 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RAB38 | 9776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RAB38 | 9776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RAB4B | 9782 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RABEP2 | 24817 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RABL2A | 9799 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RAC1 | 9801 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
RAC2 | 9802 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RAC2 | 9802 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RAD50 | 9816 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RAD54B | 17228 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RAET1E | 16793 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RAF1 | 9829 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RAF1 | 9829 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RAF1 | 9829 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RALA | 9839 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RALB | 9840 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
RALB | 9840 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
RAP1GDS1 | 9859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RAP1GDS1 | 9859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RAP2A | 9861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RAPH1 | 14436 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
RAPH1 | 14436 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
RAPH1 | 14436 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
RARA | 9864 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RARB | 9865 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
RARB | 9865 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
RARB | 9865 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
RARB | 9865 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
RARRES1 | 9867 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RASAL2 | 9874 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
RASAL2 | 9874 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
RASD1 | 15828 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RASD1 | 15828 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RASEF | 26464 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
RASEF | 26464 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
RASEF | 26464 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
RASSF2 | 9883 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RASSF6 | 20796 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
RBBP8 | 9891 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RBBP8 | 9891 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RBFA | 26120 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RBFOX3 | 27097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RBM24 | 21539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RBM24 | 21539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RBM47 | 30358 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RBMS1 | 9907 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RBMS3 | 13427 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
RBMX | 9910 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RBMXL1 | 25073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RBP1 | 9919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
RBP1 | 9919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
RBP4 | 9922 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RBP4 | 9922 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RBPMS | 19097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
RBPMS | 19097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
RBX1 | 9928 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RCCD1 | 30457 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RDH10 | 19975 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
RECQL4 | 9949 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
REPIN1 | 17922 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RESF1 | 25559 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RET | 9967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
REX1BD | 26098 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RFC1 | 9969 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
RFC5 | 9973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RFK | 30324 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RFPL1 | 9977 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RFPL2 | 9979 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RFTN1 | 30278 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
RFTN1 | 30278 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
RGS2 | 9998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
RHBDL2 | 16083 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
RHCG | 18140 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
RHNO1 | 28206 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RHOBTB1 | 18738 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RHOBTB1 | 18738 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RHOD | 670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
RHOD | 670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
RHOQ | 17736 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RHOT1 | 21168 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RHOT1 | 21168 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RHOT1 | 21168 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RHOU | 17794 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RHPN1 | 19973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RHPN2 | 19974 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RHPN2 | 19974 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RIC3 | 30338 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RIOK3 | 11451 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RIPK2 | 10020 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RMI1 | 25764 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RNASE4 | 10047 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
RND1 | 18314 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RNF103 | 12859 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RNF122 | 21147 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RNF144B | 21578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
RNF144B | 21578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
RNF152 | 26811 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RNF152 | 26811 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RNF157 | 29402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
RNF157 | 29402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
RNF157 | 29402 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
RNF19B | 26886 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RNF213 | 14539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RNF213 | 14539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RNF213 | 14539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RNF213 | 14539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RNF213 | 14539 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RNF217-AS1 | 50866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RNF32-DT | 48971 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RNFT2 | 25905 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RNH1 | 10074 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RNPEP | 10078 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RNU6ATAC5P | 34095 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29316740
|
ROR1 | 10256 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ROR1 | 10256 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RPAIN | 28641 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RPAIN | 28641 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RPGR | 10295 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RPL31P11 | 35849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RPP25L | 19909 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RPRD1B | 16209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RPS12 | 10385 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29316740
|
RPS27L | 18476 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RPS27L | 18476 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RPS6KA1 | 10430 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
RPS6KA3 | 10432 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RPS6KA6 | 10435 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
RPS6KA6 | 10435 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RPS6KA6 | 10435 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RRNAD1 | 24273 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RRP7BP | 30454 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29316740
|
RSKR | 26314 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RSPO3 | 20866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RSPO3 | 20866 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
RSRC1 | 24152 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
RTN3 | 10469 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RTN4IP1 | 18647 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RTN4IP1 | 18647 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
RUNX2 | 10472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
RUNX2 | 10472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
S100A14 | 18901 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 35229723
|
S100A14 | 18901 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
S100A14 | 18901 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
S100A16 | 20441 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
S100A16 | 20441 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
S100A2 | 10492 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
S100A2 | 10492 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
S100A4 | 10494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 25881239
|
S100A4 | 10494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0074 | 25881239
|
S100A8 | 10498 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
S100A8 | 10498 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 29416721
|
S100A8 | 10498 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
S100A8 | 10498 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
S100A9 | 10499 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 29416721
|
S100P | 10504 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0106 | 34059086
|
S100P | 10504 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0106 | 25881239
|
S1PR1 | 3165 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
SAA1 | 10513 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SAA1 | 10513 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SACS | 10519 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
SACS | 10519 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
SAMD1 | 17958 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SAMD9 | 1348 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SAMD9 | 1348 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SARS2 | 17697 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SARS2 | 17697 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SAT1 | 10540 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
SATB2 | 21637 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SAYSD1 | 21025 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SC5DL | 10547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SC5DL | 10547 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SCAF4 | 19304 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SCCPDH | 24275 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SCFD2 | 30676 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29316740
|
SCGB3A1 | 18384 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SCML2 | 10581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SCML2 | 10581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SCN9A | 10597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SCNN1A | 10599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
SCO1 | 10603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SDC4 | 10661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SDC4 | 10661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SDC4P | 18903 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SDCBP2 | 15756 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SDF2 | 10675 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SDHA | 10680 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 34059086
|
SDR42E1 | 29834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SDR42E1 | 29834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SEBOX | 32942 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
SEC14L2 | 10699 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SEC14L2 | 10699 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SEC16A | 29006 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SEC16B | 30301 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SEC24D | 10706 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SEL1L3 | 29108 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SELENOP | 10751 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
SELENOW | 10752 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SELPLG | 10722 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
SEMA3A | 10723 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SEMA3A | 10723 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SEMA4F | 10734 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SEMA4F | 10734 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SEMA7A | 10741 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
SEMA7A | 10741 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
SERINC2 | 23231 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
SERINC2 | 23231 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
SERINC5 | 18825 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SERPINB1 | 3311 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
SERPINB2 | 8584 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SERPINB2 | 8584 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SERPINB3 | 10569 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
SERPINB5 | 8949 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
SERPINB5 | 8949 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
SERPINB8 | 8952 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SERPINB8 | 8952 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SERPINB9 | 8955 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SERPINB9 | 8955 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SERPINE1 | 8583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
SERPINE1 | 8583 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
SERPINE2 | 8951 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SERPINE2 | 8951 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SERPINF1 | 8824 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SERPINF1 | 8824 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SERTAD1 | 17932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SERTAD4 | 25236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SESN3 | 23060 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SETD1A | 29010 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SF3B3 | 10770 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SFI1 | 29064 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SFMBT2 | 20256 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
SFMBT2 | 20256 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
SFN | 10773 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
SFN | 10773 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
SFRP1 | 10776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SFRP1 | 10776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SFRP4 | 10778 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SFRS3 | 10785 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0032 | 18034892
|
SGCA | 10805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SGCD | 10807 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SGCD | 10807 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SGCE | 10808 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SGCE | 10808 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SGK3 | 10812 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SGMS2 | 28395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SH2D4A | 26102 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
SH2D4A | 26102 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SH3BGRL | 10823 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
SH3BGRL3 | 15568 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
SH3PXD2A | 23664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
SH3PXD2A | 23664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
SH3RF2 | 26299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SH3RF2 | 26299 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SHARPIN | 25321 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SIDT1 | 25967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SIGLEC11 | 15622 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
SIGLEC16 | 24851 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
SIPA1L1 | 20284 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SIPA1L1 | 20284 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SIPA1L2 | 23800 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SIRPB2 | 16247 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SIRPG-AS1 | 51229 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SIRT1 | 14929 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SIRT1 | 14929 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SIRT3 | 14931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SIRT5 | 14933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SIRT5 | 14933 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SIRT6 | 14934 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SIRT7 | 14935 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SKAP2 | 15687 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SKI | 10896 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SKP2 | 10901 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
SLAIN1 | 26387 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC10A7 | 23088 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC10A7 | 23088 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC12A2 | 10911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
SLC12A2 | 10911 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
SLC16A2 | 10923 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC16A4 | 10925 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC16A9 | 23520 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC1A3 | 10941 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SLC20A1 | 10946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC20A1 | 10946 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC20A2 | 10947 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC20A2 | 10947 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC22A15 | 20301 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC22A3 | 10967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC22A3 | 10967 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC23A1 | 10974 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SLC23A2 | 10973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC23A2 | 10973 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC25A1 | 10979 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SLC25A30 | 27371 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC25A42 | 28380 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SLC26A10 | 14470 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC27A2 | 10996 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SLC27A2 | 10996 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SLC28A2 | 11002 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
SLC29A1 | 11003 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SLC2A1 | 11005 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SLC2A1 | 11005 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SLC2A3 | 11007 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
SLC2A3 | 11007 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
SLC2A9 | 13446 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC30A7 | 19306 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC31A2 | 11017 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC31A2 | 11017 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC37A2 | 20644 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC37A2 | 20644 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC38A5 | 18070 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC38A5 | 18070 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC38A6 | 19863 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SLC38A6 | 19863 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SLC39A11 | 14463 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC40A1 | 10909 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC40A1 | 10909 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC41A2 | 31045 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC41A2 | 31045 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC43A1 | 9225 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SLC43A3 | 17466 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC43A3 | 17466 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC44A2 | 17292 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC44A2 | 17292 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC44A3-AS1 | 49057 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SLC45A4 | 29196 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC45A4 | 29196 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC47A1 | 25588 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SLC47A1 | 25588 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SLC4A3 | 11029 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SLC4A4 | 11030 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
SLC4A4 | 11030 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SLC4A4 | 11030 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SLC52A2 | 30224 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SLC5A11 | 23091 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SLC5A6 | 11041 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SLC5A6 | 11041 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SLC5A6 | 11041 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SLC66A3 | 28503 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC6A10P | 11043 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC6A10P | 11043 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC6A11 | 11044 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC6A11 | 11044 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC6A15 | 13621 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC6A16 | 13622 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC6A6 | 11052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC6A6 | 11052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC6A8 | 11055 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC6A8 | 11055 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC7A11 | 11059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SLC7A2 | 11060 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SLC7A2 | 11060 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SLC7A5P2 | 24951 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 31692042
|
SLC7A7 | 11065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC7A7 | 11065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC7A8 | 11066 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
SLC8A1 | 11068 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
SLC8A2 | 11069 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SLC9A1 | 11071 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC9A1 | 11071 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SLC9A2 | 11072 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC9A2 | 11072 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLC9A3R1 | 11075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SLC9B2 | 25143 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLC9B2 | 25143 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLCO1B3 | 10961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SLCO1B3 | 10961 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SLF1 | 25408 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLF1 | 25408 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SLFN12 | 25500 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLFN12 | 25500 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLFN5 | 28286 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SLMAP | 16643 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SLPI | 11092 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 34059086
|
SLX4IP | 16225 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SMARCA1 | 11097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SMARCA1 | 11097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SMARCA4 | 11100 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SMCR6 | NA | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SMG1P1 | 44186 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 31692042
|
SMIM14 | 27321 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SMIM31 | 49638 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SMOX | 15862 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SMOX | 15862 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SMTN | 11126 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SMURF2 | 16809 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SMURF2 | 16809 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SNAI2 | 11094 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0159 | 25881239
|
SNAI2 | 11094 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0159 | 25881239
|
SNAP25 | 11132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SNAP25 | 11132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SNAPC5 | 15484 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SNAPC5 | 15484 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SNCA | 11138 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SNCA | 11138 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SNED1 | 24696 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
SNHG11 | 25046 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SNHG12 | 30062 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SNORA11 | 32599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29316740
|
SNORA61 | 32655 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SNORA70D | 34356 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SNORA75 | 32661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SNORA78 | 32664 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SNORD14C | 30352 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SNORD36B | 10164 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SNORD41 | 10179 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29316740
|
SNORD42B | 10181 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SNORD42B | 10181 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SNORD4A | 10097 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SNORD4B | 10098 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SNORD4B | 10098 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SNORD75 | 32735 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SNORD91A | 32752 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SNRNP25 | 14161 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SNX29 | 30542 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SOCS6 | 16833 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SOCS6 | 16833 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SOGA3 | 21494 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SORBS1 | 14565 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
SORL1 | 11185 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SORL1 | 11185 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SOWAHC | 26149 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
SOWAHC | 26149 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
SOX21 | 11197 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
SOX8 | 11203 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
SP1 | 11205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SP100 | 11206 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SP2 | 11207 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SPAG5 | 13452 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SPARC | 11219 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SPARC | 11219 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SPATA17 | 25184 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SPATA18 | 29579 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SPCS3 | 26212 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SPCS3 | 26212 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SPIDR | 28971 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SPINT1 | 11246 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SPINT1 | 11246 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SPOCK1 | 11251 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SPOCK1 | 11251 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SPOCK2 | 13564 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SPON1 | 11252 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
SPP1 | 11255 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
SPP1 | 11255 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SPR | 11257 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SPR | 11257 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SPRR1B | 11260 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SPRR1B | 11260 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SPTLC3 | 16253 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SPTSSA | 20361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
SPX | 28139 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SQLE | 11279 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SQOR | 20390 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
SQOR | 20390 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
SQSTM1 | 11280 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
SRCIN1 | 29506 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
SREK1IP1 | 26716 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SREK1IP1 | 26716 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SRGN | 9361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SRGN | 9361 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SRPX | 11309 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SRPX | 11309 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
SRPX2 | 30668 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
SRSF2 | 10783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SRXN1 | 16132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SRXN1 | 16132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SRXN1 | 16132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SRXN1 | 16132 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
SSBP2 | 15831 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SSBP3 | 15674 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SSH2 | 30580 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ST14 | 11344 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ST3GAL6 | 18080 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ST6GAL2 | 10861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ST6GAL2 | 10861 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ST6GALNAC2 | 10867 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ST6GALNAC2 | 10867 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ST8SIA4 | 10871 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
ST8SIA4 | 10871 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
STAB1 | 18628 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
STARD3 | 17579 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
STARD4 | 18058 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
STARD4 | 18058 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
STARD5 | 18065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
STARD5 | 18065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
STARD5 | 18065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
STAT1 | 11362 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
STEAP1 | 11378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
STEAP1 | 11378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
STEAP2 | 17885 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
STIMATE | 30526 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
STING1 | 27962 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
STK11 | 11389 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
STK17A | 11395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
STK17A | 11395 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
STK32B | 14217 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
STK32B | 14217 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
STK35 | 16254 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
STN1 | 26200 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
STRADB | 13205 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
STRBP | 16462 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
STRIP2 | 22209 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
STRN | 11424 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
STX6 | 11441 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
STXBP4 | 19694 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
STXBP4 | 19694 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SUCLA2 | 11448 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SULF2 | 20392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SULF2 | 20392 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
SULT1C2 | 11456 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
SUMO3 | 11124 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SYCP2 | 11490 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 25881239
|
SYK | 11491 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SYK | 11491 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
SYNM | 24466 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SYNM | 24466 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SYT1 | 11509 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
SYT17 | 24119 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SYT17 | 24119 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
SYT3 | 11511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
SYT7 | 11514 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
SYTL1 | 15584 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 35229723
|
SYTL1 | 15584 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
SZRD1 | 30232 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TAC3 | 11521 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
TACC2 | 11523 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TACO1 | 24316 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TACSTD2 | 11530 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
TAGLN3 | 29868 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TAGLN3 | 29868 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TANC2 | 30212 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TAOK1 | 29259 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TBC1D1 | 11578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TBC1D1 | 11578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TBC1D15 | 25694 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TBC1D2 | 18026 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TBC1D2 | 18026 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TBC1D30 | 29164 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TBC1D31 | 30888 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TBC1D31 | 30888 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TBC1D8 | 17791 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TBX18 | 11595 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TBX18 | 11595 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TBX3 | 11602 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
TBX4 | 11603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TCEA1 | 11612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TCEA1 | 11612 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TCF7 | 11639 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TCF7L1 | 11640 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TCIM | 1357 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TCIM | 1357 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TCOF1 | 11654 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
TCP11L2 | 28627 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TEAD4 | 11717 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TEC | 11719 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TECTA | 11720 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TENM2 | 29943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TENM2 | 29943 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TERT | 11730 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
TERT | 11730 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
TESC | 26065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TESC | 26065 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TET1 | 29484 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TEX9 | 29585 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TFAP2C | 11744 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TFDP1 | 11749 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TFDP2 | 11751 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TFF1 | 11755 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TFG | 11758 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TFPI | 11760 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TFPI | 11760 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TFPI2 | 11761 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
TFPI2 | 11761 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
TGFA | 11765 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TGFA | 11765 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TGFBR3 | 11774 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TGFBR3 | 11774 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
THBS1 | 11785 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
THBS1 | 11785 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
THRA | 11796 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
THRA | 11796 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
THSD4 | 25835 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
THSD7A | 22207 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
THSD7A | 22207 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TICRR | 28704 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TIGD1 | 14523 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TIGD5 | 18336 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TIMELESS | 11813 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TIMM10 | 11814 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TIMP1 | 11820 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
TIMP1 | 11820 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
TIMP2 | 11821 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TIMP2 | 11821 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TIMP3 | 11822 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
TIMP3 | 11822 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
TIMP3 | 11822 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
TIMP3 | 11822 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
TINAG | 14599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
TINAG | 14599 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
TINAGL1 | 19168 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TINAGL1 | 19168 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TIPARP | 23696 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TIPARP | 23696 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TIPARP | 23696 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TIPIN | 30750 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TJP2 | 11828 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TKT | 11834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
TKT | 11834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
TLCD1 | 25177 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TLCD1 | 25177 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TLCD2 | 33522 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TLCD4 | 26477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TLCD4 | 26477 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TLE1 | 11837 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TLE1 | 11837 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TLNRD1 | 13519 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TLR3 | 11849 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TLR4 | 11850 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TLR4 | 11850 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TLR5 | 11851 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TLR6 | 16711 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TLR6 | 16711 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TM4SF1 | 11853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
TM4SF1 | 11853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
TM4SF1 | 11853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0053 | 18034892
|
TM4SF1 | 11853 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0053 | 18034892
|
TM4SF18 | 25181 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TM4SF18 | 25181 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TM4SF20 | 26230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TM4SF20 | 26230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TMBIM1 | 23410 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TMC6 | 18021 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TMC7 | 23000 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TMC8 | 20474 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TMCC3 | 29199 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TMCO3 | 20329 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TMCO4 | 27393 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TMEFF2 | 11867 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TMEM106B | 22407 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TMEM115 | 30055 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TMEM120B | 32008 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TMEM145 | 26912 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TMEM147 | 30414 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TMEM154 | 26489 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TMEM154 | 26489 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TMEM156 | 26260 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TMEM167B | 30187 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TMEM167B | 30187 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TMEM171 | 27031 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TMEM176B | 29596 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TMEM184B | 1310 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TMEM185B | 18896 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TMEM198B | 43629 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TMEM2 | 11869 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TMEM205 | 29631 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TMEM225B | 53075 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TMEM230 | 15876 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TMEM30B | 27254 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TMEM40 | 25620 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TMEM40 | 25620 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TMEM43 | 28472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TMEM43 | 28472 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TMEM45A | 25480 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
TMEM45A | 25480 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 25881239
|
TMEM45B | 25194 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
TMEM50B | 1280 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TMEM54 | 24143 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TMEM60 | 21754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TMEM63B | 17735 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TMEM63C | 23787 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TMEM87A | 24522 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TMEM97 | 28106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
TMEM97 | 28106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TMEM97 | 28106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TMEM97 | 28106 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TMPO | 11875 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TMPRSS11D | 24059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TMPRSS11D | 24059 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TMPRSS7 | 30846 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TMUB2 | 28459 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TNC | 5318 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TNC | 5318 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TNF | 11892 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TNFAIP1 | 11894 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TNFAIP3 | 11896 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
TNFAIP3 | 11896 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 25881239
|
TNFRSF10A | 11904 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TNFRSF1A | 11916 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TNFRSF4 | 11918 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TNFSF10 | 11925 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TNFSF10 | 11925 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TNFSF13 | 11928 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TNFSF15 | 11931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TNIP1 | 16903 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TNIP1 | 16903 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TNNT1 | 11948 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TNNT1 | 11948 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TNS3 | 21616 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TNS3 | 21616 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TNS4 | 24352 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
TNS4 | 24352 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 25881239
|
TOM1L1 | 11983 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TOMM22 | 18002 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TOMM34 | 15746 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TOP1MT | 29787 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TOP2B | 11990 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TOX3 | 11972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
TOX3 | 11972 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TP53 | 11998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TP53I3 | 19373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 29316740
|
TP53I3 | 19373 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
TP53INP1 | 18022 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29316740
|
TP63 | 15979 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TP63 | 15979 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TPBG | 12004 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
TPBG | 12004 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29416721
|
TPD52L1 | 12006 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
TPD52L2 | 12007 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TPM2 | 12011 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TPM4 | 12013 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 34059086
|
TPST1 | 12020 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TPST1 | 12020 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TRAF3IP2 | 1343 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TRAF3IP2 | 1343 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TRAF4 | 12034 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TRAF4 | 12034 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TRAM2 | 16855 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TRAPPC1 | 19894 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TRERF1 | 18273 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TRIM14 | 16283 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TRIM16 | 17241 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TRIM16 | 17241 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TRIM16L | 32670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TRIM16L | 32670 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TRIM22 | 16379 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TRIM25 | 12932 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TRIM29 | 17274 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
TRIM29 | 17274 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 25881239
|
TRIML2 | 26378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TRIML2 | 26378 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
TRIOBP | 17009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TRIP13 | 12307 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
TRMT10A | 28403 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TRMT10A | 28403 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TRMT10C | 26022 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TRMT10C | 26022 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TRO | 12326 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29416721
|
TRPA1 | 497 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TRPA1 | 497 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TRPS1 | 12340 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TRPS1 | 12340 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TSC2 | 12363 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TSKU | 28850 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TSPAN1 | 20657 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TSPAN1 | 20657 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
TSPAN5 | 17753 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TSPAN5 | 17753 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TSPAN6 | 11858 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
TSPAN6 | 11858 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
TSTD1 | 35410 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TSTD1 | 35410 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TTBK2 | 19141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TTC39B | 23704 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TUBA4A | 12407 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TUBB4A | 20774 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TUBB4A | 20774 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TUBB6 | 20776 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
TUBD1 | 16811 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TUBD1 | 16811 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TUBGCP4 | 16691 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
TUBGCP6 | 18127 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
TXNIP | 16952 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 35229723
|
TXNRD1 | 12437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
TXNRD1 | 12437 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
U2AF1L4 | 23020 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
UAP1 | 12457 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
UAP1 | 12457 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
UBA1 | 12469 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 34059086
|
UBA2 | 30661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
UBA2 | 30661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
UBA6 | 25581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
UBA6 | 25581 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
UBALD2 | 28438 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
UBB | 12463 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
UBE2C | 15937 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
UBE2E3 | 12479 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
UBR1 | 16808 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
UBTF | 12511 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
UBXN11 | 30600 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
UCHL1 | 12513 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
UCHL3 | 12515 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
UCN2 | 18414 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
UCP2 | 12518 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
UCP2 | 12518 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
UFSP1 | 33821 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
UGCG | 12524 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
UGCG | 12524 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
UGDH | 12525 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 25881239
|
UGT2B7 | 12554 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
UGT2B7 | 12554 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
UGT8 | 12555 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
UGT8 | 12555 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
UHRF1BP1 | 21216 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
UNC93B1 | 13481 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
UNG | 12572 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 25881239
|
UPF3B | 20439 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
UPK1B | 12578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
UPK1B | 12578 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
UPP1 | 12576 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
UPP1 | 12576 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
UQCRFS1 | 12587 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
UQCRFS1 | 12587 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
URI1 | 13236 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
USP11 | 12609 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
USP11 | 12609 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
USP11 | 12609 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
USP3 | 12626 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
USP35 | 20061 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
USP7 | 12630 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
VAMP8 | 12647 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
VAPA | 12648 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
VASP | 12652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
VASP | 12652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
VAT1 | 16919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
VAV2 | 12658 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
VCAN | 2464 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29416721
|
VCAN | 2464 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
VCAN | 2464 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
VCPIP1 | 30897 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
VDR | 12679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
VDR | 12679 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
VEGFA | 12680 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
VEGFA | 12680 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
VEGFC | 12682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
VEGFC | 12682 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
VGLL3 | 24327 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
VGLL3 | 24327 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
VIL1 | 12690 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA and FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 35229723
|
VPS37B | 25754 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
VSIG8 | 32063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
VSNL1 | 12722 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
VSNL1 | 12722 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
VSTM2A | 28499 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
VTI1B | 17793 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
WASF2 | 12733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
WASHC5 | 28984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
WASHC5 | 28984 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
WDFY2 | 20482 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
WDFY2 | 20482 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
WDR17 | 16661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
WDR17 | 16661 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
WDR35 | 29250 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
WDR35 | 29250 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
WDR47 | 29141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
WDR47 | 29141 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
WDR72 | 26790 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
WDR72 | 26790 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
WDR77 | 29652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
WDR77 | 29652 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
WDR91 | 24997 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
WIPI1 | 25471 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
WLS | 30238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
WLS | 30238 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
WNT7A | 12786 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
WNT7A | 12786 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
XAGE1A | 4111 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
XAGE1A | 4111 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
XDH | 12805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
XDH | 12805 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
XPC | 12816 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
XPNPEP3 | 28052 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
XPO6 | 19733 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
XPO7 | 14108 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
YAF2 | 17363 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
YTHDC2 | 24721 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZBED2 | 20710 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZBED2 | 20710 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZBTB20 | 13503 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZBTB20 | 13503 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZBTB48 | 4930 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZC2HC1C | 20354 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZC3HAV1 | 23721 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZDHHC3 | 18470 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ZFAND5 | 13008 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZFAND5 | 13008 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZFAND6 | 30164 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZFHX4 | 30939 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZFHX4 | 30939 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZFP36L1 | 1107 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ZFP36L2 | 1108 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZFP41 | 26786 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ZFPM1 | 19762 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZKSCAN2 | 25677 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZNF146 | 12931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZNF146 | 12931 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZNF181 | 12971 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF185 | 12976 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
ZNF185 | 12976 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ZNF185 | 12976 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ZNF20 | 12992 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF20 | 12992 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF215 | 13007 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ZNF253 | 13497 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF260 | 13499 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF267 | 13060 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0011 | 18034892
|
ZNF275 | 13069 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF28 | 13073 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF280A | 18597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF280A | 18597 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF280C | 25955 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF30 | 13090 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF30 | 13090 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF302 | 13848 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZNF302 | 13848 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZNF331 | 15489 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZNF385A | 17521 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZNF397 | 18818 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 34059086
|
ZNF426 | 20725 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF426 | 20725 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF461 | 21629 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF462 | 21684 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF468 | 33105 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ZNF468 | 33105 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ZNF486 | 20807 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ZNF486 | 20807 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ZNF507 | 23783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF507 | 23783 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF512 | 29380 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZNF518A | 29009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZNF518A | 29009 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZNF528 | 29384 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF528 | 29384 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF532 | 30940 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZNF558 | 26422 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF561 | 28684 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ZNF566 | 25919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF566 | 25919 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF567 | 28696 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SP assay followed by Transcriptomics | Up | 0.04 | 0.0021 | 18034892
|
ZNF569 | 24737 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF574 | 26166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZNF618 | 29416 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZNF625 | 30571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ZNF625 | 30571 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ZNF626 | 30461 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF630 | 28855 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ZNF641 | 31834 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ZNF649 | 25741 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ZNF671 | 26279 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ZNF688 | 30489 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZNF696 | 25872 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZNF711 | 13128 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF724 | 32460 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF728 | 32463 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZNF766 | 28063 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 25881239
|
ZNF780A | 27603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZNF780A | 27603 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 25881239
|
ZNF787 | 26998 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZNF790 | 33114 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF790 | 33114 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF808 | 33230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF808 | 33230 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF83 | 13158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF83 | 13158 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF860 | 34513 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ZNF860 | 34513 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 25881239
|
ZNF90 | 13165 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF90 | 13165 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF91 | 13166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ZNF91 | 13166 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ZNF93 | 13169 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZNF93 | 13169 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 25881239
|
ZSCAN20 | 13093 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 34059086
|
ZSWIM9 | 34495 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZXDB | 13199 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|
ZYX | 13200 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 25881239
|
ZZEF1 | 29027 | HTM | Non Small Cell Lung Cancer | Carcinoma | A549 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 34059086
|